Disc Medicine (IRON) 10-K 27 Feb 25 2024 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Feb. 21, 2025	Jun. 30, 2024
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Trading Symbol	IRON
Entity Registrant Name	Disc Medicine, Inc.
Entity Central Index Key	0001816736
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		34,569,042
Entity File Number	001-39438
Entity Tax Identification Number	85-1612845
Entity Address, Address Line One	321 Arsenal Street, Suite 101
Entity Address, City or Town	Watertown
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02472
City Area Code	617
Local Phone Number	674-9274
Entity Incorporation, State or Country Code	DE
Title of 12(b) Security	Common Stock, $0.0001 Par Value
Security Exchange Name	NASDAQ
Entity Public Float			$ 983
Document Annual Report	true
Document Transition Report	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s Proxy Statement for its 2025 Annual Meeting of Stockholders, which the registrant intends to file with the Securities and Exchange Commission not later than 120 days after the registrant’s fiscal year ended December 31, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K.
Auditor Firm ID	42
Auditor Name	Ernst & Young LLP
Auditor Location	Boston, Massachusetts
Auditor Opinion	We have audited the accompanying consolidated balance sheets of Disc Medicine, Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 27, 2025 expressed an adverse opinion thereon.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 192,434	$ 360,382
Marketable securities	297,447	0
Prepaid expenses and other current assets	3,734	5,280
Total current assets	493,615	365,662
Property and equipment, net	751	170
Right-of-use assets, operating leases	1,569	1,930
Other assets	838	234
Total assets	496,773	367,996
Current liabilities:
Accounts payable	7,948	12,629
Accrued external research and development expenses	7,141	1,986
Other accrued expenses	8,097	6,159
Operating lease liabilities, current	130	665
Total current liabilities	23,316	21,439
Long-term debt, net	28,322	0
Operating lease liabilities, non-current	1,548	1,436
Total liabilities	53,186	22,875
Commitments and contingencies (Note 15)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued or outstanding as of December 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 100,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 29,865,030 and 24,360,233 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively	3	2
Additional paid-in capital	741,297	533,764
Accumulated other comprehensive income	289	0
Accumulated deficit	(298,002)	(188,645)
Total stockholders' equity	443,587	345,121
Total liabilities and stockholders' equity	$ 496,773	$ 367,996

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2024	Dec. 31, 2023
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	29,865,030	24,360,233
Common stock, shares outstanding	29,865,030	24,360,233

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating expenses:
Research and development	$ 96,671	$ 69,264
Selling, general and administrative	33,049	21,861
Total operating expenses	129,720	91,125
Loss from operations	(129,720)	(91,125)
Other income (expense), net:
Interest income	21,292	14,797
Interest expense	(572)	0
Other expense	(2)	(2)
Total other income (expense), net	20,718	14,795
Loss before income taxes	(109,002)	(76,330)
Income tax expense	(355)	(99)
Net loss	$ (109,357)	$ (76,429)
Net loss per share, basic	$ (3.96)	$ (3.42)
Net loss per share, diluted	$ (3.96)	$ (3.42)
Weighted-average common shares outstanding-basic	27,606,022	22,315,877
Weighted-average common shares outstanding-diluted	27,606,022	22,315,877
Comprehensive loss:
Net loss	$ (109,357)	$ (76,429)
Other comprehensive income:
Foreign currency translation adjustments	(27)	0
Unrealized gain on marketable securities	316	0
Total other comprehensive income	289	0
Comprehensive loss	$ (109,068)	$ (76,429)

Consolidated Statements Stockho

Consolidated Statements Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2022	$ 176,600	$ 2	$ 288,814		$ (112,216)
Balance (in shares) at Dec. 31, 2022		17,403,315
Issuance of common stock upon exercise of stock options	2,763		2,763
Issuance of common stock upon exercise of stock options (in shares)		254,432
Vesting of restricted common stock (in shares)		1,916
Stock-based compensation expense	5,530		5,530
Sale of common stock in registered direct offering	34,148		34,148
Sale of common stock in registered direct offering, (in shares)		1,488,166
Foreign currency translation adjustments	0
Sale of pre-funded warrants in registered direct offering	28,206		28,206
Sale of common stock in at-the-market offerings	26,422		26,422
Sale of common stock in at-the-market offerings, (in shares)		967,264
Sale of common stock in follow-on public offering	138,508		138,508
Sale of common stock in follow-on public offering, (in shares)		3,015,919
Sale of pre-funded warrants in follow-on public offering	9,373		9,373
Issuance of common stock upon exercise of warrants		1,229,221
Net loss	(76,429)				(76,429)
Balance at Dec. 31, 2023	345,121	$ 2	533,764		(188,645)
Balance (in shares) at Dec. 31, 2023		24,360,233
Issuance of common stock upon exercise of stock options	$ 2,976		2,976
Issuance of common stock upon exercise of stock options (in shares)	315,266	315,266
Stock-based compensation expense	$ 16,815		16,815
Issuance of common stock under employee stock purchase plan (in shares)		11,082
Issuance of common stock under employee stock purchase plan	441		441
Foreign currency translation adjustments	(27)			$ (27)
Unrealized gain on marketable securities	316			316
Sale of common stock in at-the-market offerings	14,790		14,790
Sale of common stock in an underwritten offering	172,512	$ 1	172,511
Sale of common stock in at-the-market offerings, (in shares)		234,449
Sale of common stock in an underwritten offering, (in shares)		4,944,000
Net loss	(109,357)				(109,357)
Balance at Dec. 31, 2024	$ 443,587	$ 3	$ 741,297	$ 289	$ (298,002)
Balance (in shares) at Dec. 31, 2024		29,865,030

Consolidated Statements Stock_2

Consolidated Statements Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Common stock in registered direct offering, net of issuance costs		$ 80
Pre-funded warrants in registered direct offering, net of issuance costs		66
Common stock in at-the-market offerings, net of issuance costs	$ 518	742
Common stock in follow-on public offering, net of issuance costs		9,272
Pre-funded warrants in follow-on public offering, net of issuance costs		$ 627
Sale of common stock in underwritten direct offering	$ 5,472

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net loss	$ (109,357)	$ (76,429)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization	156	100
Stock-based compensation	16,815	5,530
Amortization/accretion of investment securities	(5,304)	0
Non-cash lease expense	433	290
Non-cash interest expense	127	0
Other non-cash items	(27)	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	1,571	(1,166)
Accounts payable	(4,681)	(3,741)
Accrued external research and development expenses	5,155	169
Other accrued expenses	1,681	1,839
Operating lease liabilities	(495)	(54)
Net cash used in operating activities	(93,926)	(73,462)
Cash flows from investing activities:
Purchases of property and equipment	(505)	(89)
Purchases of marketable securities	(386,627)	0
Maturities of marketable securities	94,800	0
Net cash used in investing activities	(292,332)	(89)
Cash flows from financing activities:
Proceeds from issuance of long-term debt, net of issuance costs paid	28,988	0
Payment of debt issuance costs	(1,393)	0
Proceeds from sale of common stock in offerings, net of issuance costs paid	172,512	199,078
Proceeds from sale of pre-funded warrants in offerings, net of issuance costs paid	0	37,579
Proceeds from sale of common stock in at-the-market offerings, net of issuance costs paid	14,790	0
Proceeds from stock option exercises	2,976	2,722
Contributions from employee stock purchase plan	441	0
Net cash provided by financing activities	218,314	239,379
Net (decrease) increase in cash, cash equivalents and restricted cash	(167,944)	165,828
Cash, cash equivalents and restricted cash, beginning of period	360,616	194,788
Cash, cash equivalents and restricted cash, end of period	192,672	360,616
Supplemental cash flow information
Cash paid for income taxes	299	112
Cash paid for interest	198	0
Cash paid for amounts included in the measurement of operating lease liabilities	718	186
Supplemental disclosure of non-cash activities
Purchases of property and equipment included in accounts payable and accrued expenses	245	13
Right-of-use assets obtained in exchange for new operating lease liabilities	0	1,106
Net increase (decrease) in right-of-use assets related to lease modifications and reassessment events	72	(317)
Net increase (decrease) in operating lease liabilities related to lease modifications and reassessment events	72	(287)
Deferred issuance costs on sale of pre-funded warrants in registered direct offering included in accounts payable and accrued expenses	0	225
Receivable for proceeds from stock option exercises included in other current assets	$ 114	$ 41

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (109,357)	$ (76,429)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	The following table discloses any officer (as defined in Rule 16a-1(f) under the Exchange Act) or director who entered into, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during the three months ended December 31, 2024: Name and Title Type of Trading Arrangement Action Taken Duration or End Date Aggregate Number of Securities to be Sold Description of Trading Arrangement William Savage , M.D., Ph.D. Chief Medical Officer Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) Adoption November 18, 2024 ) End Date May 30, 2025 ) Up to 21,870 Sale
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10b5-1 Arrangement Modified	false
Non-Rule 10b5-1 Arrangement Modified	false
William Savage [Member]
Trading Arrangements, by Individual
Name	William Savage
Title	Chief Medical Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	November 18, 2024
Expiration Date	May 30, 2025
Arrangement Duration	193 days
Aggregate Available	21,870

Cybersecurity Risk Management,

Cybersecurity Risk Management, Strategy and Governance	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	ITEM 1C. CYBERSECURITY Cyber Risk Management and Strategy Disc Medicine, under the oversight of the audit committee of the board of directors, has implemented and maintains processes to review and manage enterprise risks, including annual assessments of cybersecurity risks, across the Company. Our cybersecurity risk management program, which is informed by and incorporates elements of recognized industry standards, is designed to identify, assess, and mitigate critical risks from cybersecurity threats. This program includes, but is not limited to, ongoing monitoring for potential critical risks from cybersecurity threats using automated tools. To support our cybersecurity risk management program, we leverage a managed service provider, or MSP, that provides ongoing support for the protection of our information technology infrastructure as well as a virtual Chief Information Security Officer, or vCISO. Our cybersecurity risk management strategy is informed by periodic conversations with, and risk assessments conducted by, our vCISO. We have an employee security awareness training program, offered upon employee onboarding and on an annual basis, that is designed to raise awareness of cybersecurity threats across functions as well as to encourage consideration of cybersecurity risks across our Company. As part of this employee training program, we periodically conduct phishing simulations designed to raise employee awareness of such risks. We have also implemented a process to review contractual requirements related to information security obligations included in our agreements with certain third-party vendors and service providers, as appropriate. We have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition ; however, like other companies in our industry, we and our third-party vendors may, from time to time, experience threats and security incidents relating to our and our third-party vendors’ information systems and infrastructure. For more information, please see Item 1A - Risk Factors. Governance Related to Cybersecurity Risks Our Head of Information Technology, or IT, under the oversight of our Chief Legal Officer, is responsible for the administration and maintenance of our cybersecurity risk management program, including the day-to-day oversight of the assessment and management of cybersecurity risks. The individual who currently holds the title of Head of IT has more than 20 years of experience in information security and cybersecurity risk management. Our Head of IT directly reports to, and meets periodically with, our Chief Legal Officer to discuss and review our cybersecurity risk management processes, with input from the Company’s MSP and vCISO, as appropriate. Our board of directors has delegated oversight of the Company’s cybersecurity program to the audit committee of the board of directors. As provided in the audit committee charter, the audit committee is responsible for reviewing and discussing the Company’s information security and risk management programs, controls, and procedures, including high-level review of the threat landscape facing the Company and the Company’s strategy to mitigate cybersecurity risks and potential breaches. Under the audit committee charter, the audit committee is also responsible for reviewing the recovery and communication plans for any unplanned outage, cybersecurity incident, or data breach. Our Head of IT, twice a year, provides reports to the audit committee on the status of our cybersecurity program, including measures implemented to monitor and address risks from cybersecurity threats, as appropriate. He also reports on a quarterly basis to the executive committee on cybersecurity and information technology matters. The chair of the audit committee provides periodic reports on cybersecurity risk management to the full board of directors. Our Chief Legal Officer, on an annual basis, discusses the results of our enterprise risk assessment processes, including risks related to cybersecurity, with the full board of directors.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Our Head of Information Technology, or IT, under the oversight of our Chief Legal Officer, is responsible for the administration and maintenance of our cybersecurity risk management program, including the day-to-day oversight of the assessment and management of cybersecurity risks. The individual who currently holds the title of Head of IT has more than 20 years of experience in information security and cybersecurity risk management. Our Head of IT directly reports to, and meets periodically with, our Chief Legal Officer to discuss and review our cybersecurity risk management processes, with input from the Company’s MSP and vCISO, as appropriate. Our board of directors has delegated oversight of the Company’s cybersecurity program to the audit committee of the board of directors. As provided in the audit committee charter, the audit committee is responsible for reviewing and discussing the Company’s information security and risk management programs, controls, and procedures, including high-level review of the threat landscape facing the Company and the Company’s strategy to mitigate cybersecurity risks and potential breaches. Under the audit committee charter, the audit committee is also responsible for reviewing the recovery and communication plans for any unplanned outage, cybersecurity incident, or data breach. Our Head of IT, twice a year, provides reports to the audit committee on the status of our cybersecurity program, including measures implemented to monitor and address risks from cybersecurity threats, as appropriate. He also reports on a quarterly basis to the executive committee on cybersecurity and information technology matters. The chair of the audit committee provides periodic reports on cybersecurity risk management to the full board of directors. Our Chief Legal Officer, on an annual basis, discusses the results of our enterprise risk assessment processes, including risks related to cybersecurity, with the full board of directors.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our Head of IT directly reports to, and meets periodically with, our Chief Legal Officer to discuss and review our cybersecurity risk management processes, with input from the Company’s MSP and vCISO, as appropriate. Our board of directors has delegated oversight of the Company’s cybersecurity program to the audit committee of the board of directors. As provided in the audit committee charter, the audit committee is responsible for reviewing and discussing the Company’s information security and risk management programs, controls, and procedures, including high-level review of the threat landscape facing the Company and the Company’s strategy to mitigate cybersecurity risks and potential breaches. Under the audit committee charter, the audit committee is also responsible for reviewing the recovery and communication plans for any unplanned outage, cybersecurity incident, or data breach.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our Head of IT, twice a year, provides reports to the audit committee on the status of our cybersecurity program, including measures implemented to monitor and address risks from cybersecurity threats, as appropriate. He also reports on a quarterly basis to the executive committee on cybersecurity and information technology matters.
Cybersecurity Risk Role of Management [Text Block]	Our Head of Information Technology, or IT, under the oversight of our Chief Legal Officer, is responsible for the administration and maintenance of our cybersecurity risk management program, including the day-to-day oversight of the assessment and management of cybersecurity risks. The individual who currently holds the title of Head of IT has more than 20 years of experience in information security and cybersecurity risk management. Our Head of IT directly reports to, and meets periodically with, our Chief Legal Officer to discuss and review our cybersecurity risk management processes, with input from the Company’s MSP and vCISO, as appropriate. Our board of directors has delegated oversight of the Company’s cybersecurity program to the audit committee of the board of directors. As provided in the audit committee charter, the audit committee is responsible for reviewing and discussing the Company’s information security and risk management programs, controls, and procedures, including high-level review of the threat landscape facing the Company and the Company’s strategy to mitigate cybersecurity risks and potential breaches. Under the audit committee charter, the audit committee is also responsible for reviewing the recovery and communication plans for any unplanned outage, cybersecurity incident, or data breach.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our board of directors has delegated oversight of the Company’s cybersecurity program to the audit committee of the board of directors. As provided in the audit committee charter, the audit committee is responsible for reviewing and discussing the Company’s information security and risk management programs, controls, and procedures, including high-level review of the threat landscape facing the Company and the Company’s strategy to mitigate cybersecurity risks and potential breaches. Under the audit committee charter, the audit committee is also responsible for reviewing the recovery and communication plans for any unplanned outage, cybersecurity incident, or data breach.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	The individual who currently holds the title of Head of IT has more than 20 years of experience in information security and cybersecurity risk management.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	Our Head of IT, twice a year, provides reports to the audit committee on the status of our cybersecurity program, including measures implemented to monitor and address risks from cybersecurity threats, as appropriate. He also reports on a quarterly basis to the executive committee on cybersecurity and information technology matters. The chair of the audit committee provides periodic reports on cybersecurity risk management to the full board of directors.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Organization and Nature of the

Organization and Nature of the Business	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of the Business	1. Organization and Nature of the Business Disc Medicine, Inc. (together with its subsidiaries, the “Company”) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The Company’s current pipeline includes bitopertin for the treatment of erythropoietic porphyrias (“EPs”) including erythropoietic protoporphyria (“EPP”), X-linked protoporphyria (“XLP”), and Diamond-Blackfan Anemia (“DBA”); DISC-0974 for the treatment of anemia of myelofibrosis (“MF”) and anemia of chronic kidney disease (“CKD”); and DISC-3405 for the treatment of polycythemia vera (“PV”) and other hematologic disorders. In addition, the Company’s preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The Company’s approach to product candidate development leverages well-understood molecular mechanisms that have been validated in humans. The Company believes that each of its product candidates, if approved, has the potential to improve the lives of patients suffering from hematologic diseases. The Company was founded in October 2017. The Company’s principal offices are located in Watertown, Massachusetts. The Company is subject to a number of risks and uncertainties common to development stage companies in the biotechnology industry, including, but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, reliance on third-party organizations, protection of proprietary technology, compliance with government regulations, the impact of public health crises such as pandemics and the ability to secure additional capital to fund operations. The Company’s research and development programs will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. Reverse Merger with Gemini On August 9, 2022, Gemini Therapeutics, Inc., a Delaware corporation (“Gemini”), Gemstone Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gemini (“Merger Sub”), and Disc Medicine, Inc., a Delaware corporation (“Private Disc”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”). The merger was completed on December 29, 2022. In accordance with the Merger Agreement, the Merger Sub merged with and into Private Disc, with Private Disc surviving as a wholly-owned subsidiary of the Company (the “merger”). Gemini changed its name to Disc Medicine Inc., and Private Disc, which remains as a wholly-owned subsidiary of the Company, changed its name to Disc Medicine Opco, Inc. On December 30, 2022, the combined company’s common stock began trading on The Nasdaq Capital Market under the ticker symbol “IRON.” Except as otherwise indicated, references herein to “Disc,” the “Company,” or the “combined company”, refer to Disc Medicine, Inc. on a post-merger basis, and the term “Private Disc” refers to the business of privately-held Disc Medicine, Inc., prior to completion of the merger. References to Gemini refer to Gemini Therapeutics, Inc. prior to completion of the merger. In connection with the merger, each person who was a stockholder of record of Gemini or had the right to receive Gemini’s common stock received a contractual contingent value right (“CVR”) issued by Gemini subject to and in accordance with the terms and conditions of a Contingent Value Rights Agreement (the “CVR Agreement”), representing the contractual right to receive consideration from the post-closing combined company upon the receipt of certain proceeds from a disposition of Gemini’s pre-merger assets (specifically, Gemini’s intellectual property assets (“Gemini IP”), which the Company assumed in the merger) during the period that is one year after the closing of the merger, calculated in accordance with the CVR Agreement. To satisfy its obligations with respect to the CVRs and the Gemini IP, the Company hired an outside firm to attempt to sell the Gemini IP, which firm previously was unsuccessful in finding a buyer for the Gemini IP. In June 2023, the Company received an offer for the Gemini IP and recorded a $ 1.5 million liability representing the estimated fair value of the Company’s obligation to the holders of the CVRs based on the offer. However, the counterparty and the Company were unable to come to an agreement on the terms of the offer. The disposition period ended December 29, 2023 and no dispositions of Gemini's pre-merger assets were made during the disposition period. Therefore, there were no CVR payments made to the holders and there will not be any future CVR payments to the holders (see Note 3 - Fair Value Measurements ). As such, the Company’s obligations under the CVR Agreement have expired and the CVRs are valueless. In December 2023, the Company recognized the reversal of the $ 1.5 million liability in the consolidated statements of operations and comprehensive loss. The Company generated no revenue from Gemini’s pre-merger assets and incurred approximately $ 1.6 million in aggregate costs (including maintenance of license agreements, storage, legal and other fees) for the year ended December 31, 2023, to maintain Gemini’s pre-merger assets solely in order to fulfill the Company’s obligations under the CVR Agreement. Liquidity and Capital Resources The Company’s consolidated financial statements have been prepared on the basis of the Company continuing as a going concern. The Company expects that its existing cash, cash equivalents and marketable securities as of December 31, 2024 of $ 489.9 million will enable the Company to fund its planned operating expense and capital expenditure requirements for at least twelve months from the date of issuance of these consolidated financial statements. The Company has incurred recurring losses and negative cash flows from operations since inception. As of December 31, 2024, the Company had an accumulated deficit of $ 298.0 million. The Company expects its operating lo sses and negative operating cash flows to continue into the foreseeable future. The future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. There can be no assurance that the Company will ever earn revenues or achieve profitability, or if achieved, that the revenues or profitability will be sustained on a continuing basis. In addition, the Company’s preclinical and clinical development activities, manufacturing and commercialization of the Company’s product candidates, if approved, may require significant additional financing.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The Company’s consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. Certain reclassifications have been made to prior periods to conform to current period presentation. Reclassification of prior year amounts have been made to separately present accrued external research and development costs from other accrued expenses. There was no impact on total current liabilities or total liabilities resulting from these reclassifications. Use of Estimates The preparation of the Company’s consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to accrued research and development expenses; stock-based compensation expense; the fair value of the common stock prior to the effective date of the merger; and income taxes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it has concluded to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ materially from those estimates or assumptions. Segment Informatio n The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions, resulting in a single reportable segment. The Company has determined that its chief operating decision maker is its Chief Executive Officer. The Company’s chief operating decision maker reviews the Company’s financial information on a consolidated basis for purposes of allocating resources and assessing financial performance. All of the Company’s tangible assets are held in the United States. See Note 17 - Segment Information for additional details. Concentration of Credit Risk and of Significant Suppliers Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and limits its exposure to cash risk by placing its cash with high credit quality accredited financial institutions. The Company has concluded that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and to process its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the manufacturing process or supply chain. Comprehensive Income (Loss) Comprehensive income (loss) is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) and the change in accumulated other comprehensive income (loss) for the period. Accumulated other comprehensive income (loss) consisted of foreign currency translation adjustments and unrealized gains (losses) on available-for-sale marketable securities during the year ended December 31, 2024. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking and money market accounts and U.S. treasury securities with original maturities of three months or less at the date of purchase. Cash equivalents are reflected at fair value based on quoted market prices as further described in Note 3 - Fair Value Measurements . Marketable Securities The Company classifies its marketable securities as available-for-sale. All of the Company’s marketable securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date. Marketable securities are maintained by an investment manager and consist of U.S. treasury and government agency securities. Marketable securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income (loss) as a component of stockholders’ equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the underlying marketable security. Although these marketable securities are available to be sold to meet operating needs or otherwise, they are generally held through maturity. The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense), net within the consolidated statements of operations and comprehensive loss. The Company reviews its portfolio of available-for-sale securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit loss or other factors. If the decline in fair value is due to credit loss factors, a loss is recognized. To date, the Company has not experienced any credit losses and does not expect it is exposed to any significant credit risk on these investments. Deferred Transaction Costs The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred transaction costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the transaction, either as a reduction of the carrying value of the preferred stock or in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the transaction. Should the in-process equity financing be abandoned, the deferred transaction costs would be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss. Fair Value Measurements The Company categorizes its assets and liabilities measured at fair value in accordance with the provisions of ASC 820, Fair Value Measurements and Disclosures, which establishes a consistent framework for measuring fair value and expands disclosures for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: • Level 1—Quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level 2—Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and • Level 3—Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing. The fair value of the Company’s cash equivalents are determined according to the fair value hierarchy described above (see Note 3 - Fair Value Measurements ). The carrying values of the Company’s prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Estimated Useful Life Leasehold improvements Shorter of useful life or remaining life of lease Computer equipment 3.0 years Furniture and fixtures 3.0 years Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated in accordance with the above guidelines once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are expensed as incurred. The Company capitalizes internal costs incurred to develop software for internal use during the application development stage. The Company includes capitalized internally developed software subject to a cloud computing arrangement within other assets. Amortization of capitalized internally developed software costs is recorded in depreciation expense over the estimated useful life of the related asset of 3.0 years. Impairment of Long-lived Assets The Company accounts for the impairment and disposition of long-lived assets in accordance with ASC Topic 360, Property, Plant, and Equipment . Long-lived assets, such as property and equipment and right-of-use ("ROU") assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. The recoverability of assets or asset groups to be held and used is measured by a comparison of the carrying amount of an asset or asset group to estimated undiscounted future cash flows expected to be generated by the asset or asset group. If the carrying amount of an asset or asset group exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset or asset group exceeds the estimated fair value of the asset or asset group. There were no impairment losses recorded for the years ended December 31, 2024 and 2023 . Leases The Company accounts for its leases under ASC Topic 842, Leases . Upon adoption, the Company elected to combine lease and non-lease components when calculating minimum lease payments on new leases for all asset classes. The Company has also elected an accounting policy to forgo the recognition of lease assets or liabilities for short-term leases. Short-term leases are defined, in accordance with the standard, as those with terms of one year or less and do not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The Company determines if an arrangement is or contains a lease at contract inception. The Company accounts for a contract as a lease when it has the right to direct the use of the asset for a period of time while obtaining substantially all of the asset’s economic benefits. The Company determines the initial classification and measurement of right-of-use assets and lease liabilities at the lease commencement date and thereafter at the modification date, if modified. Right-of-use assets represent the Company's right to control the underlying assets under lease, and the lease liability is the Company's obligation to make the lease payments related to the underlying assets under lease, over the contractual term. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of future minimum fixed lease payments to be made over the lease term. The Company uses the non-cancellable lease term unless it is reasonably certain that a renewal or termination option will be exercised. When available, the Company will use the rate implicit in the lease to discount lease payments to present value. As most leases do not provide an implicit rate, the Company will estimate the incremental borrowing rate to discount the lease payments. The Company estimates the incremental borrowing rate based on the rates of interest that the Company would have to pay to borrow an amount equal to the lease payments on a collateralized basis, over a similar term, and in a similar economic environment. The right-of-use asset also includes any lease prepayments and initial direct costs, offset by lease incentives. Certain lease agreements contain variable lease payments which are not included in the measurement of the lease liability. Variable lease payments relate to taxes, insurance, utilities, and common area maintenance ("CAM"). These variable lease payments are recognized in the consolidated statements of operations and comprehensive loss in the period in which the obligation for those payments is incurred. Research and Development Expenses Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, depreciation, external costs of vendors engaged to conduct preclinical development activities and clinical trials, manufacturing expenses, as well as the costs of licensing technology. Nonrefundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the services rendered. If the Company acquires an asset or group of assets under an in-licensing arrangement that does not meet the definition of a business under ASC Topic 805, Business Combinations , and the acquired in-process research and development does not have an alternative future use, any related upfront license payment is expensed as incurred in accordance with guidance in ASC Topic 730, Research and Development . Where contingent milestone payments are due to third parties under license or other agreements, the milestone payment obligations are recognized as expense when achievement of the contingent milestone is probable, which is generally upon achievement of the milestone event. Any contingent payments that qualify as a derivative liability are recognized at fair value on the Company’s consolidated balance sheets. Annual maintenance fees under license agreements are expensed in the period in which they are incurred. Contingent payments for assets acquired are expensed as incurred or capitalized and amortized based on the nature of the associated asset at the date the payment is recognized. Royalties owed on sales of the products licensed pursuant to license agreements are expensed in the period the related revenues are recognized. The Company has entered into various research, development and manufacturing contracts with research institutions and other companies primarily in the United States, including contracts with third-party contract research organizations and contract development and manufacturing organizations. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accrued liabilities for estimated ongoing research, development and manufacturing costs and prepaid expenses for payments made in advance of work performed. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations to those third parties as of period end. Any accrual estimates are based on a number of factors, including the Company’s knowledge of the progress towards completion of the research, development and manufacturing activities, invoicing to date under the contracts, communication from the research institutions and other companies of any actual costs incurred during the period that have not yet been invoiced and the costs included in the contracts. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results may differ from the estimates made by the Company. Amortization of Debt Discount and Issuance Costs Long-term debt is initially recorded as the proceeds received by the Company, net of debt issuance costs and discounts. Debt is subsequently stated at amortized cost. Debt issuance costs and discounts and are amortized to interest expense using the effective interest method, over the term of the debt. Debt issuance costs and discounts related to a recognized debt liability are presented in the consolidated balance sheets as a direct deduction from the carrying amount of that debt liability. For tranches not yet drawn , the related debt issuance costs are deferred and recorded as an asset. In the consolidated statements of cash flows, debt issuance costs paid to lenders are netted against the proceeds from the related long-term debt while debt issuance costs paid to third parties, are presented separately within financing activities. Patent Costs The Company expenses all costs as incurred in connection with patent applications, including direct application fees, and the legal and consulting expenses related to making such applications due to the uncertainty about the recovery of the expenditure. These costs are included in selling, general and administrative expenses within the Company’s consolidated statements of operations and comprehensive loss. Stock-Based Compensation The Company accounts for all stock-based awards granted to employees and non-employees as stock-based compensation expense at fair value in accordance with ASC 718, Compensation - Stock Compensation . The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the fair value of the Company’s common stock on the date of grant, the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option and the Company’s expected dividend yield. Due to the lack of company-specific historical and implied volatility data, the Company determines the volatility for awards granted based on an analysis of reported data for a group of guideline companies that issued options with substantially similar terms. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of guideline companies. The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company’s stock options granted to employees has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on its common stock; therefore, the expected dividend yield is assumed to be zero. The grant date fair value of restricted stock units and shares of restricted stock granted is based on the fair value of the underlying common stock on the date of grant. The Company recognizes compensation expense for employees and non-employees over the requisite service period, which is generally the vesting period of the respective award, based on the grant date fair value of the award. For awards that include performance-based vesting conditions expense is recognized using the accelerated attribution method when the performance condition is deemed to be probable. The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in the consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. See Note 12 - Stock-Based Compensation for a summary of the stock-based award activity under the Company’s stock-based compensation plans. Determination of Fair Value of Common Stock on Grant Dates Prior to the merger, due to the absence of an active market for Private Disc’s common stock, Private Disc and its Board were required to determine the fair value of Private Disc’s common stock at the time of each grant of a stock-based award. Private Disc estimated the fair value of its common stock utilizing methodologies in accordance with the framework of the American Institute of Certified Public Accountants’ Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation . In determining the exercise prices for options granted, Private Disc considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including prices paid for Private Disc’s convertible preferred stock and the rights, preferences, and privileges of Private Disc’s Preferred Stock and common stock; Private Disc’s stage of development and status of technological developments within Private Disc’s research; the illiquid nature of securities in a private company; the prospects of a liquidity event; and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. Private Disc’s common stock valuations were prepared using either an option pricing method (“OPM”), or a hybrid method, both of which used market approaches to estimate our enterprise value. The OPM treats common stock and convertible preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company’s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceeds the value of the convertible preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock. The hybrid method is a probability-weighted expected return method (“PWERM”), by which the equity value in one or more scenarios is calculated using an OPM. The PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values for the company, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. In addition to a scenario using the OPM, the hybrid method also considers an initial public offering scenario in which the shares of convertible preferred stock are assumed to convert to common stock. The future value of the common stock in the initial public offering scenario was discounted back to the valuation date at an appropriate risk adjusted discount rate. In the hybrid method, the present value indicated for each scenario was probability weighted to arrive at an indication of value for the Private Disc’s common stock. Private Disc utilized significant estimates and assumptions in determining the fair value of its equity and equity-based awards. Substantially all of the awards granted by the Company are either new hire grants or routine annual grants. Management evaluates its award grants and modifications contemporaneously and if any are determined to be spring-loaded, the Company will adjust the fair value. Income Taxes Income taxes have been accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Since the Company has generated operating losses and expects to continue to incur future losses, the net deferred tax assets have been fully offset by a valuation allowance. The Company accounts for income taxes in accordance with authoritative accounting guidance which states the impact of an uncertain income tax position is recognized at the largest amount that is “more likely than not” to be sustained upon audit by the relevant taxing authority. There are no unrecognized tax benefits included in the Company’s consolidated balance sheets at December 31, 2024 or 2023. The Company’s practice is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties related to income tax matters in its consolidated statements of operations and comprehensive loss since inception. The Company files federal income tax returns in the United States, the Netherlands and Australia and state income tax returns in Massachusetts and various other state jurisdictions. The Company’s income tax returns are subject to review and tax assessment from an income tax examination. As of December 31, 2024 , the Company was not under examination by the Internal Revenue Service or other jurisdictions for any tax year. Net Loss Per Share Basic and diluted net loss per share is computed by dividing net loss by the weighted-average common shares outstanding. The weighted-average common shares outstanding used in the basic and diluted net loss per share calculation includes the pre-funded warrants issued in connection with the Company’s follow-on public offering in June 2023 and registered direct offering in February 2023 as the pre-funded warrants are exercisable for nominal cash consideration. In periods in which the Company reports a net loss, diluted net loss per share is generally the same as basic net loss per share since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. Recently Adopted Accounting Pronouncements On January 1, 2024, the Company adopted ASU 2023-07, Segment Reporting: Improvements to Reportable Segment Disclosures , which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Refer to Note 17 - Segment Information for additional details. Recently Issued Accounting Pronouncements Not Yet Adopted Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The following tables present information about the Company’s assets and liabilities that are regularly measured and carried at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value, which is described further within Note 2 - Summary of Significant Accounting Policies . Financial assets and liabilities measured at fair value on a recurring basis are summarized as follows (in thousands): ​ December 31, 2024 ​ Level 1 ​ Level 2 ​ Level 3 Assets ​ ​ ​ Cash equivalents: ​ ​ ​ Money market funds ​ $ 88,735 ​ $ — ​ $ — U.S. treasury securities ​ — ​ 91,916 ​ — Total cash equivalents 88,735 91,916 — Marketable securities: U.S. treasury securities — 189,663 — U.S. government agency securities — 107,784 — Total marketable securities — 297,447 — Total assets ​ $ 88,735 ​ $ 389,363 ​ $ — ​ December 31, 2023 ​ Level 1 Level 2 Level 3 Assets ​ ​ ​ Cash equivalents: ​ ​ ​ Money market funds ​ $ 55,001 ​ $ — ​ $ — U.S. treasury securities ​ — ​ 255,419 ​ — Total cash equivalents 55,001 255,419 — Total assets ​ $ 55,001 ​ $ 255,419 ​ $ — The fair value of the Company’s Level 1 cash equivalents, consisting of money market funds, is based on quoted market prices in active markets with no valuation adjustment. The fair value of the Company’s Level 2 cash equivalents and marketable securities, consisting of U.S. treasury and U.S. government agency securities with original maturities of three months or less and twelve months or less, respectively, are determined through third-party pricing services. The amortized cost of cash equivalents approximates the fair value. There have been no impairments of the Company’s assets measured and carried at fair value during the years ended December 31, 2024 and 2023. In addition, there were no changes in valuation techniques or transfers between Level 1, Level 2 and Level 3 financial assets during the years ended December 31, 2024 and 2023. The Company did not have any non-recurring fair value measurements on any assets or liabilities during the years ended December 31, 2024 and 2023. As described in Note 1 - Organization and Nature of the Business , in connection with the merger, the stockholders of Gemini received a CVR to receive consideration from the Company upon its receipt of certain proceeds, resulting from a disposition of Gemini’s pre-merger assets within one year after the closing of the merger, calculated in accordance with the CVR Agreement. The disposition period ended December 29, 2023 and no dispositions of Gemini's pre-merger assets were made during the disposition period. Therefore, there were no CVR payments made to the holders and there will not be any future CVR payments to the holders. The fair value of the CVR liability was zero as of December 31, 2024 and 2023, respectively.

Marketable Securities

Marketable Securities	12 Months Ended
	Dec. 31, 2024
Marketable Securities [Abstract]
Marketable Securities	4. Marketable Securities Marketable securities as of December 31, 2024 consisted of the following (in thousands): ​ Gross Unrealized ​ Amortized Cost ​ Gains ​ Losses ​ Estimated Fair Value Marketable securities available-for-sale: ​ U.S. treasury securities $ 189,409 $ 288 $ ( 34 ) ​ $ 189,663 U.S. government agency securities 107,722 85 ( 23 ) 107,784 Total available-for-sale securities $ 297,131 $ 373 $ ( 57 ) ​ $ 297,447 Marketable securities as of December 31, 2023 were zero . As of December 31, 2024 , all marketable securities had an original maturity date of twelve months or less. The aggregate fair value of marketable securities with unrealized losses was $ 51.0 million as of December 31, 2024 and zero as of December 31, 2023. As of December 31, 2024 and December 31, 2023 , five investments and no investments, respectively, were in an unrealized loss position. All such investments have been in an unrealized loss position for less than a year and these losses are considered temporary. The Company has the ability and intent to hold these investments until a recovery of their amortized cost, which may not occur until maturity. The Company expects that U.S. treasury and U.S. government agency securities are subject to minimal credit risk. As a result, the Company did no t record any charges for credit-related impairments for its available-for-sale securities for the years ended December 31, 2024 and 2023 .

Cash, Cash Equivalents and Rest

Cash, Cash Equivalents and Restricted Cash	12 Months Ended
	Dec. 31, 2024
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Restricted Cash	5. Cash, Cash Equivalents and Restricted Cash Cash, cash equivalents and restricted cash consisted of the following (in thousands): ​ December 31, December 31, ​ 2024 ​ 2023 Cash and cash equivalents $ 192,434 $ 360,382 Restricted cash 238 ​ 234 Total cash, cash equivalents and restricted cash as shown on the consolidated statements of cash flows $ 192,672 $ 360,616 The Company's restricted cash balance, which is classified within other assets on the consolidated balance sheets, consists of letters of credit related to leased and subleased office space in Watertown, Massachusetts. The Company is required to maintain a separate cash balance to secure its letters of credit.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	6. Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): December 31, December 31, 2024 2023 Leasehold improvements $ 566 $ — Furniture and fixtures 355 184 Computer equipment 231 231 Less: Accumulated depreciation ( 401 ) ( 245 ) Property and equipment, net $ 751 $ 170 Depreciation expense for the years ended December 31, 2024 and 2023 was $ 0.2 million and $ 0.1 million, respectively.

Other Accrued Expenses

Other Accrued Expenses	12 Months Ended
	Dec. 31, 2024
Accrued Liabilities [Abstract]
Other Accrued Expenses	7. Other Accrued Expenses Other accrued expenses consisted of the following (in thousands): December 31, December 31, 2024 2023 Accrued employee-related expenses $ 7,211 $ 5,790 Accrued professional fees 531 317 Accrued other 355 52 Total other accrued expenses $ 8,097 $ 6,159

Leases

Leases	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Leases	8. Leases The Company has an operating lease and sublease for office space which serves as the Company's corporate headquarters. The Company's sublease and lease expire in November 2026 and December 2029 , respectively. The Company's leases do not contain any material residual value guarantees or restrictive covenants. Operating leases are recognized on the consolidated balance sheets as right-of-use assets, operating leases, operating lease liabilities, current and operating lease liabilities, non-current. Operating lease expense is recognized on a straight-line basis over the lease term within the Company’s consolidated statements of operations and comprehensive loss. In August 2024, the Company amended its lease of 7,566 square feet of office space which serves as the Company’s corporate headquarters. The lease was amended to extend the term from November 30, 2026 through December 31, 2029. The Company accounted for this amendment as a modification which resulted in the application of a new incremental borrowing rate and the recognition of an additional right-of-use asset and lease liability of $ 0.1 million, inclusive of a tenant improvement allowance of $ 0.5 million. In connection with the August 2024 amendment, the Company entered into a forward-starting lease of office space on the second floor of its corporate headquarters, which the Company is currently subleasing. The forward-starting lease is expected to commence on December 1, 2026 immediately following the conclusion of the sublease, and has a term date of December 31, 2029. The Company expects to make undiscounted payments of $ 1.0 million over the term of the lease, inclusive of a tenant improvement allowance of $ 0.3 million. The impact of the forward-starting lease is not currently recorded on the Company’s consolidated balance sheets as of the reporting date. The Company will record the impact upon lease commencement. The components of lease expense were as follows (in thousands): ​ Year Ended ​ 2024 ​ 2023 Operating lease costs ​ $ 641 ​ $ 422 Variable lease costs ​ 486 ​ 159 Total lease expense ​ $ 1,127 ​ $ 581 Other information related to the Company’s leases is as follows: ​ Year Ended ​ 2024 ​ 2023 Weighted-average remaining lease term ​ 3.5 years ​ 2.9 years Weighted-average discount rate 10.3 % ​ 10.0 % The following table presents the future minimum lease payments under the Company's lease liabilities as of December 31, 2024, (in thousands): ​ Operating Leases 2025 ​ $ 324 2026 ​ 768 2027 ​ 285 2028 ​ 389 2029 401 Total minimum lease payments ​ $ 2,167 Less: imputed interest ​ ( 489 ) Lease liabilities ​ $ 1,678 Operating lease maturity amounts in the table above include tenant improvement allowance reimbursements of $ 0.5 million which are expected to be received in 2025. The table does not include contractual rent payments under the forward-starting lease which are expected to total $ 1.0 million, net of a tenant improvement allowance of $ 0.3 million on an undiscounted basis.

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Long-Term Debt	9. Long-Term Debt On November 6, 2024 (the "Closing Date"), the Company entered into a Loan and Security Agreement (the “Hercules Loan Agreement”), with the lenders party thereto (the “Lenders”) and Hercules Capital, Inc., as administrative agent and collateral agent (the “Agent”). The Hercules Loan Agreement provides for up to $ 200.0 million of senior secured term loans available to the Company in multiple tranches (the “Term Loan Facility”). Under the Hercules Loan Agreement, the Company borrowed an initial amount of $ 30.0 million on the Closing Date, and at the Company's sole option, can draw an additional $ 80.0 million on or prior to December 15, 2026, as well as additional term loan advances in an aggregate principal amount of up to $ 65.0 million during the term of the Term Loan Facility subject to achievement of specified performance milestones, and one additional term loan advance up to an aggregate principal amount of $ 25.0 million subject to certain terms and conditions. The Company intends to use the proceeds of the Term Loan Facility for working capital and general corporate purposes. The Term Loan Facility will mature on December 1, 2029 (the “Maturity Date”). The outstanding principal balance of the Term Loan Facility bears cash interest at a floating annual rate equal to the greater of (i) 8.25 % and (ii) the sum of the Prime Rate and 1.75 %. Accrued interest is payable monthly following the funding of each term loan advance. Borrowings under the Hercules Loan Agreement are repayable in monthly interest-only payments through November 2028. At the end of the interest-only payment period, borrowings under the Hercules Loan Agreement are repayable in equal monthly payments of principal and accrued interest until the Maturity Date. At the Company's option, the Company may prepay all or a portion of the outstanding borrowings, subject to a prepayment fee of 3.0 % of the principal amount if prepayment occurs during the 18 months following the Closing Date, 2.0 % after 18 months following the Closing Date but prior to 36 months following the Closing Date, and 1.0 % thereafter. The obligations under the Hercules Loan Agreement are secured, subject to customary permitted liens and other agreed-upon exceptions, by a first-priority perfected security interest in all of the tangible and intangible assets of the Company, other than intellectual property. The Hercules Loan Agreement includes customary repayment and prepayment terms, events of default, affirmative and negative covenants and representations and warranties. Additionally, the Hercules Loan Agreement contains a minimum cash covenant that requires the Company to maintain certain levels of cash in accounts subject to a control agreement in favor of the Agent at all times beginning on the first day on or after January 1, 2027 (or January 1, 2028, if the Company achieves a certain milestone) on which the aggregate principal amount of the term loan advances is then more than $ 50.0 million; provided, however, the minimum cash covenant will be waived during all times that the Company's market capitalization is greater than or equal to $ 1.0 billion. The Hercules Loan Agreement also includes a subjective acceleration clause for circumstances which could be reasonably expected to have a material adverse effect on the Company. The Company recorded debt discount and debt issuance costs of $ 1.8 million upon closing of the Hercules Loan Agreement. The Hercules Loan Agreement also provides for a final payment ("End of Term Charge"), payable upon maturity or the repayment of the obligations in full or in part (on a pro rata basis), equal to 6.75 % of the aggregate principal amount of term loans advanced to the Company and repaid on such date, which is being a ccrued on the Company's consolidated balance sheets. As of December 31, 2024 , the amount accrued for the End of Term Charge was $ 0.1 million. Debt discount and unamortized debt issuance costs were recorded as a reduction of the carrying amount on the term loan and are amortized as interest expense using the effective-interest method. In addition, unamortized deferred financing costs of $ 0.6 million w ere recorded in other assets as of December 31, 2024 related to the Company's right to borrow additional amounts in the future. Interest expense for the year ended December 31, 2024 was $ 0.6 million. As of December 31, 2024, the carrying value of the Term Loan Facility approximates its fair value. The obligations under the Term Loan Facility as of December 31, 2024 consisted of the following (in thousands): December 31, 2024 Principal term loan balance $ 30,000 Unamortized debt discount and issuance costs ( 1,746 ) Accrued end of term fee 68 Long-term debt, net $ 28,322 The annual principal payments due under the Term Loan Facility as of December 31, 2024 were as follows (in thousands): 2025 $ — 2026 — 2027 — 2028 2,200 2029 27,800 Total $ 30,000 The table of future principal payments excludes the End of Term Charge of $ 2.0 million, which is due upon the maturity of the loan.

Development and License Agreeme

Development and License Agreements	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Development and License Agreements	10. Development and License Agreements License Agreement with Oak Bay Biosciences, Inc. (“OBB”) In December 2024, the Company entered into an out-license agreement with OBB pursuant to which the Company granted an exclusive license, with the right to grant sublicenses, to certain Gemini IP. Under the terms of the agreement, the Company received an upfront payment of $ 0.2 million with additional consideration receivable upon the achievement of certain clinical, regulatory and sales milestones up to $ 7.0 million, $ 35.0 million, and $ 160.0 million, respectively. As of December 31, 2024 , none of the milestones had been achieved and are not considered probable of achievement. License and Stock Purchase Agreement with AbbVie Deutschland GmbH & Co. KG (“AbbVie”) In September 2019, the Company entered into an agreement with AbbVie, pursuant to which AbbVie granted the Company an exclusive license, with the right to grant sublicenses, to certain AbbVie intellectual property. Under this agreement, the Company paid a non-refundable, non-creditable upfront fee of $ 0.6 million. The Company is also obligated to make future payments upon the achievement of certain development, commercialization and sales-based milestones up to $ 18.0 million, $ 45.0 million and $ 87.5 million, respectively on a licensed product-by-licensed product basis. In addition, the Company is also obligated to pay royalties based on net sales of the licensed products on a licensed product-by-licensed product and country-by-country basis. As of December 31, 2024 , none of the milestones had been achieved. The Company’s royalty obligation expires on a licensed product-by-licensed product and country-by-country basis upon the expiration of the last-to-expire valid claim under the licensed intellectual property rights in such country. Unless terminated earlier, the agreement expires upon the expiration of the Company’s royalty obligation for all licensed products. AbbVie can terminate the agreement if the Company fails to make any payments within a specified period after receiving written notice of such failure, or in the event of a material breach by the Company and failure to cure such breach within a certain period of time. The Company made the first milestone payment associated with the license agreement with AbbVie in January 2025, refer to Note 18 – Subsequent Events for additional details. License Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively “Roche”) In connection with a license agreement with Roche, (the "Roche Agreement"), the Company paid Roche an upfront, non-refundable exclusivity payment of $ 0.5 million in March 2021. Upon execution of the Roche Agreement in May 2021, the Company paid Roche an additional upfront, non-refundable payment of $ 4.0 million. The Company is obligated to make contingent payments to Roche up to an aggregate of $ 50.0 million in development and regulatory milestone payments for development and approval in a first indication and up to an aggregate of $ 35.0 million in development and regulatory milestone payments for development and approval in a second indication. The Company is also obligated to make contingent payments to Roche up to an aggregate of $ 120.0 million based on achievement of certain thresholds for annual net sales of licensed products. Roche is also eligible to receive tiered royalties on net sales of commercialized products, at rates ranging from high single-digits to high teens. Pursuant to the terms of the Roche Agreement and in connection with the reverse merger with Gemini, the Company issued 482,313 shares of the Company to Roche for no consideration. The next potential milestone payments include $ 10.0 million due upon the initiation of the first Phase 3 clinical trial with a licensed product in a first indication and $ 15.0 million due upon regulatory approval in the United States with a licensed product in a first indication. As of December 31, 2024 , none of the milestones had been achieved. License Agreement with Mabwell Therapeutics, Inc. ("Mabwell") In January 2023, the Company entered into an exclusive license agreement with Mabwell, pursuant to which Mabwell granted the Company an exclusive and sublicensable license to certain Mabwell intellectual property. In connection with the agreement, the Company paid Mabwell an upfront payment of $ 10.0 million in March 2023. In October 2023, the Company dosed the first patient in the Phase 1 clinical trial for DISC-3405, resulting in a milestone payment of $ 5.0 million to Mabwell. The next potential milestone payments include $ 10.0 million due upon the initiation of a Phase 2 clinical trial for DISC-3405 and $ 5.0 million due upon the initiation of a Phase 1b clinical trial with a licensed product in a second indication. As of December 31, 2024, neither of these milestones had been achieved. In addition, the Company is obligated to pay certain development and regulatory milestone payments for the licensed products, for up to three indications, up to a maximum aggregate amount of $ 127.5 million, as well as certain commercial milestone payments for certain licensed product net sales achievements, up to a maximum aggregate amount of $ 275.0 million. The Company is further obligated to pay a tiered percentage of revenue that the Company receives from its sublicensees ranging from a low third decile percentage to a low first decile percentage. In addition, the Company is obligated to pay Mabwell a royalty on annual net sales of all licensed products at a tiered rate ranging from low single-digits to high single-digits. During the years ended December 31, 2024 and 2023 , the Company recorded research and development expense related to its arrangement with Mabwell of less than $ 0.1 million and $ 15.0 million, respectively.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2024
Stockholders' Equity Note [Abstract]
Stockholders' Equity	11. Stockholders' Equity Preferred Stock T he Company was authorized to issue up to 10,000,000 shares of preferred stock with a par value of $ 0.0001 per share. As of December 31, 2024 no shares or preferred stock were issued or outstanding. Common Stock The Company was authorized to issue up to 100,000,000 shares of common stock with a par value of $ 0.0001 per share. As of December 31, 2024 , 29,865,030 shares of common stock were issued and outstanding. ATM Programs Cantor Fitzgerald & Co. (“Cantor”) On November 15, 2024, the Company entered into a Controlled Equity Offering Sales Agreement (the “Cantor ATM Agreement”) with Cantor, pursuant to which the Company may, from time to time in its sole discretion, issue and sell to or through Cantor, acting as sales agent, shares of the Company’s common stock, par value $ 0.0001 per share having an aggregate offering price of up to $ 200.0 million. This offering was made pursuant to the Company's effective registration statement on Form S-3 filed in August 2024 (the "August 2024 Shelf"). As of December 31, 2024, there been had no issuances or sales under the Cantor ATM Agreement. Jefferies LLC In October 2023, the Company entered into an Open Market Sale Agreement with Jefferies LLC as sales agent (the “ATM Agreement”) to provide for the offering, issuance and sale by the Company of up to $ 59.7 million of the Company’s common stock from time to time in ATM offerings under the January 2023 Shelf. In November 2023, the Company filed a shelf registration statement on Form S-3 with the SEC, which covered the offering, issuance and sale by the Company of up to an aggregate of $ 400.0 million of the Company’s common stock, preferred stock, debt securities, warrants or units (the “November 2023 Shelf”). On December 5, 2023, the Company and Jefferies LLC entered into an amendment to the ATM Agreement to increase the aggregate offering price of the shares of common stock that the Company may offer under the ATM Agreement from $ 59.7 million to $ 200.0 million. The material terms and conditions of the ATM Agreement otherwise remained unchanged. On November 15, 2024, the Company terminated the ATM Agreement. In connection with the termination, the Company recognized the remaining capitalized issuance costs of $ 0.6 million as selling, general and administrative expense in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024. During the years ended December 31, 2024 and 2023, the Company had sold an aggregate of 234,449 and 141,914 shares of common stock in ATM offerings under the November 2023 Shelf and pursuant to the ATM Agreement, respectively. During the years ended December 31, 2024 and 2023, aggregate gross proceeds from the transactions were $ 15.3 million and $ 7.2 million, respectively, and the Company received $ 14.8 million and $ 7.0 million in net proceeds, after deducting placement agent fees and offering expenses, respectively. In total, the Company sold an aggregate of 376,363 shares of common stock in ATM offerings under the November 2023 Shelf and pursuant to the ATM Agreement for aggregate gross proceeds of $ 22.5 million and aggregate net proceeds received of $ 21.8 million, after deducting placement agent fees and offering expenses. SVB Securities LLC In January 2023, the Company filed a shelf registration statement on Form S-3 with the SEC, which covered the offering, issuance and sale by the Company of up to an aggregate of $ 300.0 million of the Company’s common stock, preferred stock, debt securities, warrants or units (the “January 2023 Shelf”). Subsequently in January 2023, the Company entered into a Sales Agreement (the “Sales Agreement”) with SVB Securities LLC, as sales agent, to provide for the offering, issuance and sale by the Company of up to $ 100.0 million of the Company’s common stock from time to time in “at-the-market” (“ATM”) offerings under the January 2023 Shelf. Effective June 12, 2023, the ATM program with SVB Securities LLC was suspended. Following the date of the ATM suspension, the Company did not make any further sales of its common stock pursuant to the Sales Agreement. The Sales Agreement was terminated effective September 28, 2023. In connection with the ATM suspension, the Company recognized the remaining capitalized issuance costs of $ 0.3 million as selling, general and administrative expense in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2023. During the year ended December 31, 2023, the Company had sold an aggregate of 825,350 shares of common stock in ATM offerings under the January 2023 Shelf and pursuant to the Sales Agreement. During the year ended December 31, 2023, aggregate gross proceeds from the transactions were $ 20.0 million and the Company received $ 19.5 million in net proceeds, after deducting placement agent fees and offering expenses. Underwritten Offering In June 2024, the Company entered into an underwriting agreement with Leerink Partners LLC related to an underwritten offering of 4,944,000 shares of common stock of the Company, par value $ 0.0001 per share, at a price to the public of $ 36.00 per share. The Company received net proceeds of $ 172.5 million, after deducting the underwriting discount and offering expenses of $ 5.5 million. Follow-On Public Offering I n June 2023, the Company issued 3,015,919 shares of its common stock upon the completion of its public follow-on offering, which included the exercise in full by the underwriters of their option to purchase up to 420,000 additional shares of common stock, at a public offering price of $ 49.00 per share. The Company also sold, in lieu of shares of the Company’s common stock, pre-funded warrants to purchase an aggregate of 204,081 shares of common stock at a price of $ 48.9999 per pre-funded warrant. The Company received aggregate net proceeds of $ 147.9 million, after deducting offering expenses of $ 9.9 million. As of December 31, 2024 , none of the 204,081 pre-funded warrants had been exercised. The pre-funded warrants provide that the holder will not have the right to exercise any portion of its warrants if such holder, together with its affiliates, would beneficially own in excess of 24.99 % of the number of shares of Common Stock outstanding immediately after giving effect to the exercise (the “Ownership Limit”). Purchasers of the pre-funded warrants may also elect to set the initial Ownership Limit at 4.99%, 9.99% or 19.99%. Upon at least 61 days’ prior notice from the holder to the Company, the holder may increase or decrease the Ownership Limit up to 24.99 %, provided however that purchasers that select an Ownership Limit of 19.99 % or less will only be allowed to increase the Ownership Limit above 19.99% if such increase would not result in a change of control under the rules and regulations of the Nasdaq Stock Market LLC. The pre-funded warrants meet the condition for equity classification and were therefore recorded as a component of stockholders’ equity within additional paid-in capital. Registered Direct Offering In February 2023, the Company entered into a securities purchase agreement, with certain investors. Pursuant to the securities purchase agreement, the Company sold an aggregate of 1,488,166 shares of the Company’s common stock, at a purchase price of $ 23.00 per share, and with respect to a certain investor, in lieu of shares of the Company’s common stock, pre-funded warrants to purchase an aggregate of 1,229,224 shares of the Company’s common stock, at a purchase price of $ 22.9999 per pre-funded warrant, for aggregate net proceeds of $ 62.4 million, after deducting offering expenses of $ 0.1 million. In September 2023, all of the pre-funded warrants were exercised in a cashless transaction which resulted in 1,229,221 shares of common stock being issued to the investor. The pre-funded warrants provide that the holder would not have the right to exercise any portion of its warrants if such holder, together with its affiliates, would beneficially own in excess of 9.99 % of the number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise (the “Beneficial Ownership Limitation”); provided, however, that the holder may increase or decrease the Beneficial Ownership Limitation by giving 61 days’ notice, but not to any percentage in excess of 19.99 %. The investors or their affiliates were beneficial holders of more than 5 % of the Company’s capital stock. The pre-funded warrants meet the condition for equity classification and were therefore recorded as a component of stockholders’ equity within additional paid-in capital at the time of their issuance. Registration Statements Resulting from the Merger In January 2023, as a result of the merger, the Company filed a resale registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”), which covered the proposed resale or other disposition by certain stockholders of up to an aggregate of 12,635,956 shares of the Company’s common stock. The Company also filed a registration statement on Form S-8 with the SEC, which registered 1,672,599 shares of common stock issuable with respect to Private Disc options assumed by the Company pursuant to the Merger Agreement as well as 2,035,103 additional shares of common stock reserved and available for future issuance under the 2021 Plan and 180,894 additional shares of common stock reserved and available for future issuance under the 2021 Employee Stock Purchase Plan (the “2021 ESPP” ).

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	12. Stock-Based Compensation 2017 Stock Option and Grant Plan (the "Private Disc Plan") Private Disc adopted the Private Disc Plan in November 2017 reserving shares of common stock for issuance to employees, directors, and consultants. The Private Disc Plan allowed for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock awards. Recipients of stock options or stock appreciation rights were eligible to purchase shares of Private Disc’s common stock at an exercise price equal to the estimated fair market value of such stock on the date of grant. The exercise price could have been less than fair market value if the stock award was granted pursuant to an assumption or substitution for another stock award in the event of a merger or sale of Private Disc. The maximum term of options granted under the Private Disc Plan was ten years, and stock options typically vested over a four-year period. The Board could have assigned vesting terms to the stock options grants as deemed appropriate. Private Disc also had the right of first refusal to purchase any proposed disposition of shares issued under the Private Disc Plan. As it relates to restricted stock awards, Private Disc had the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. At the discretion of the Board, unvested shares held by employees, directors and consultants could have accelerated vesting in the event of a change of control of Private Disc unless assumed or substituted by the acquirer or surviving entity. Upon completion of the merger in December 2022, the Company ceased granting awards under the Private Disc Plan. 2021 Stock Option and Incentive Plan In February 2021, Gemini adopted the 2021 Stock Option and Incentive Plan (the "2021 Plan") reserving shares of common stock to grant incentive stock options or nonqualified stock options for the purchase of common stock, stock appreciation rights, restricted stock awards, restricted stock units, unrestricted stock awards, cash-based awards and dividend equivalent rights to employees, officers, directors and consultants. Upon approving the 2021 Plan in February 2021, Gemini ceased granting awards under its then existing 2017 Stock Option and Grant Plan (the "2017 Gemini Plan"). Incentive stock options may only be granted to employees. The 2021 Plan is administered by the plan administrator, which is the compensation committee of the Company’s board of directors, provided therein, which has discretionary authority, subject only to the express provisions of the 2021 Plan, to interpret the 2021 Plan; determine eligibility for and grant awards; determine form of settlement of awards (whether in cash, shares of stock, other property or a combination of the foregoing), determine, modify or waive the terms and conditions of any award; prescribe forms, rules and procedures; and otherwise do all things necessary to carry out the purposes of the 2021 Plan. The number of shares of common stock reserved for issuance under the 2021 Plan automatically increases on January 1 of each calendar year, starting on January 1, 2022 and continuing through January 1, 2031, in an amount equal to 4 % of the total number of shares of the Company’s capital stock outstanding on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Company’s board of directors. As of December 31, 2024 , 1,643,165 shares remained available for future issuance under the 2021 Plan. The exercise price of each stock option granted under the 2021 Plan is 100 % of the fair market value of the underlying stock subject to the award, determined as of the date of the grant, or such higher amount as the plan administrator may determine in connection with the grant, and the term of stock option may not be greater than ten years. The vesting and other restrictions are determined at the discretion of the plan administrator with awards generally vesting over a four-year period. 2021 Employee Stock Purchase Plan In July 2021, Gemini’s board of directors approved the 2021 Employee Stock Purchase Plan (the "2021 ESPP"). The first offering period under the 2021 ESPP began on December 1, 2021. The number of shares of common stock reserved for issuance under the 2021 ESPP automatically increases on January 1 of each calendar year, starting on January 1, 2023 and continuing through January 1, 2031, in an amount equal to the least of (a) 1 % of the total number of shares of the Company’s capital stock outstanding on the last day of the calendar month before the date of each automatic increase, (b) 43,055 shares of common stock, or (c) such number of shares determined by the Company’s board of directors. As of December 31, 2024 , 254,926 shares remained available for future issuance under the 2021 ESPP. 2021 Inducement Plan In February 2021, Gemini’s board of directors approved the 2021 Inducement Plan. The 2021 Inducement Plan is a non-stockholder approved stock plan under which equity awards are granted to induce highly-qualified prospective officers and employees who are not currently employed by the Company to accept employment and provide them with a proprietary interest in the Company. From the completion of the merger through December 31, 2024, the Company had not granted awards under the 2021 Inducement Plan. As of December 31, 2024 , 161,689 shares remained available for future issuance under the plan. Out-of-Plan Inducement Grants From time to time, the Company grants equity awards to newly hired executives as a material inducement to enter into employment with the Company. These grants are made in accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules and are issued outside the 2021 Plan, the 2021 Inducement Plan and each of the other stock incentive plans described above. The inducement grants typically include nonqualified stock options to purchase shares of the Company's common stock, as well as restricted stock unit grants representing shares of the Company's common stock. The option awards have a ten-year term, with 25 % of the underlying shares vesting and becoming exercisable on the one-year anniversary of the date of grant, and the balance of each option award vesting in equal monthly installments over 36 months thereafter. The restricted stock unit awards vest with respect to 25 % of the underlying shares on each of the first, second, third and fourth anniversaries of the vesting date as set by the Comp any policy. The inducement grants are included in the stock option and restricted stock unit tables below. During the year ended December 31, 2024 , the Company granted 220,000 nonqualified stock options to purchase shares of the Company's common stock, and 146,664 restricted stock units under employment inducement grants. The Company made no employment inducement grants during the year ended December 31, 2023. Stock Options For purposes of calculating stock-based compensation, the Company estimates the fair value of stock options using the Black-Scholes option-pricing model. This model incorporates various assumptions, including the expected volatility, expected term, and interest rates. Prior to the merger, Private Disc lacked company-specific historical and implied volatility information. Therefore, Private Disc estimated its expected stock volatility based on the historical volatility of a publicly traded set of peer public companies and the Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the option. For options with service-based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected dividend yield of 0 % is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The weighted-average assumptions used to estimate the fair value of stock options granted were as follows: Year Ended 2024 ​ 2023 Risk-free interest rate 4.00 % ​ 4.03 % Expected term (in years) 6.35 ​ 6.88 Expected volatility 60 % ​ 59 % Expected dividend yield 0 % ​ 0 % Fair value per share of common stock $ 58.99 ​ $ 43.42 The weighted-average grant date fair value of options granted in the years ended December 31, 2024 and 2023 was $ 35.36 and $ 26.54 per share, respectively. The following table summarizes stock option activity for the year ended December 31, 2024. Number of ​ Weighted- ​ Weighted- ​ Aggregate Outstanding at December 31, 2023 2,459,037 ​ $ 13.82 ​ 7.81 ​ $ 109,078 Granted 896,275 58.99 ​ ​ Exercised ( 315,266 ) 9.46 ​ ​ Forfeited ( 156,930 ) 40.46 ​ ​ Expired ( 12,752 ) 110.25 ​ ​ Outstanding at December 31, 2024 2,870,364 ​ $ 26.52 7.44 $ 106,766 Exercisable at December 31, 2024 1,589,968 $ 14.72 6.47 $ 77,702 The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the common stock as of the end of the period. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2024 and 2023 was $ 14.5 million and $ 8.3 million, respectively. The total fair value of options vested during the years ended December 31, 2024 and 2023 was $ 10.0 million and $ 3.7 million, respectively. The tax benefit from the exercise of options eligible for a tax deduction realized during the years ended December 31, 2024 and 2023 was $ 11.0 million and $ 7.2 million, respectively. Restricted Stock Units For purposes of calculating stock-based compensation, the Company determines the fair value of the restricted stock units based on the fair value of the Company’s common stock at the time of grant. The following table summarizes restricted stock unit activity for the year ended December 31, 2024. Number of Units ​ Weighted- Restricted stock units as of December 31, 2023 — ​ $ — Granted 507,303 ​ 60.26 Forfeited ( 32,163 ) 63.90 Restricted stock units as of December 31, 2024 475,140 ​ $ 60.01 Shares of Restricted Common Stock As of December 31, 2024, the Company had issued a total of 63,061 shares of restricted common stock to the founders of Private Disc pursuant to subscription agreements and to certain key employees pursuant to the Private Disc Plan at $ 0.0001 per share. The stock restrictions relate to the sale and transferability of the stock and lapse over the defined vesting period in the restricted stock agreement. The vesting period is generally contingent upon continued employment or consulting services being provided to the Company. In the event of termination, the Company had the right, but not the obligation to repurchase the unvested shares at the original purchase price. As of December 31, 2023, all awards of restricted common stock were fully vested. A summary of restricted common stock activity was as follows: December 31, 2023 Unvested at the beginning of the period 1,916 Vested ( 1,916 ) Unvested at the end of the period — Stock-Based Compensation Expense Total stock-based compensation expense recorded as research and development and selling, general and administrative expenses, respectively, for employees, directors and non-employees was as follows (in thousands): Year Ended 2024 ​ 2023 Research and development $ 7,028 ​ $ 1,767 Selling, general and administrative 9,787 ​ 3,763 Total stock-based compensation expense $ 16,815 ​ $ 5,530 The following table summarizes unrecognized stock-based compensation expense as of December 31, 2024. Unrecognized Expense ​ Weighted-Average Restricted stock units $ 23,284 ​ 3.29 Stock options 28,278 2.85 Total unrecognized equity-based compensation expense $ 51,562

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows: ​ Year Ended December 31, ​ 2024 2023 Federal statutory income tax rate ​ 21.0 % 21.0 % State income taxes, net of federal benefit ​ 6.4 % 8.0 % Federal and state research and development tax credits ​ 12.1 % 4.0 % Stock-based compensation 1.3 % 1.3 % Section 162(m) limitation ( 1.6 )% ( 0.8 )% Other ​ ( 0.1 )% 0.1 % Change in deferred tax asset valuation allowance ​ ( 39.4 )% ( 33.6 )% Effective income tax rate ​ ( 0.3 )% 0.0 % For the years ended December 31, 2024 and 2023 the Company recorded income tax expense of $ 0.4 million and $ 0.1 million, respectively, which was primarily due to state income tax resulting from interest income. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of the Company’s net deferred income taxes are as follows (in thousands): ​ December 31, ​ 2024 ​ 2023 Deferred tax assets: ​ ​ Net operating loss carryforwards ​ $ 33,209 $ 24,312 Research and experimental expenditures 39,463 20,598 Tax credits ​ 21,248 ​ 7,202 Capitalized licenses ​ 6,225 ​ 6,890 Accrued expenses 1,137 1,513 Stock-based compensation ​ 3,407 ​ 1,234 Operating lease liabilities ​ 447 ​ 574 Total deferred tax assets ​ 105,136 ​ 62,323 Valuation allowance ​ ( 104,670 ) ​ ( 61,768 ) Total deferred tax assets, net of valuation allowance ​ 466 ​ 555 Deferred tax liabilities: ​ ​ Operating right-of-use assets ​ ( 418 ) ​ ( 527 ) Depreciation ​ ( 48 ) ​ ( 28 ) Total deferred tax liabilities ​ ( 466 ) ​ ( 555 ) Net deferred tax assets ​ $ — $ — The Company's income tax provision for the twelve months ended December 31, 2024 related to state and foreign income taxes. The Company has evaluated the positive and negative evidence bearing upon the reliability of its deferred tax assets. Based on this, the Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the deferred tax assets is not determined to be more likely than not. During the year ended December 31, 2024, the valuation allowance increased by $ 42.9 million primarily due to the increase in the Company’s net operating loss, capitalized expenditures and tax credit carryforwards during the period. As of December 31, 2024 , the Company had $ 117.9 million and $ 133.8 million of federal and state operating loss carryforwards, respectively. Substantially all of the federal NOLs are not subject to expiration and the state NOLs begin to expire in 2037 . These loss carryforwards are available to reduce future federal taxable income, if any. As of December 31, 2024 , the Company also had federal and state research and development tax credit carryforwards of $ 19.0 million and $ 2.8 million respectively, to offset future income taxes, which will begin to expire in December 2034 . These loss carryforwards are subject to review and possible adjustment by the appropriate taxing authorities. Utilization of the Company’s NOL carryforwards and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section 382 as well as similar state provisions. These ownership changes may limit the amount of NOL and research and development credit carryforwards that can be utilized annually to offset future taxable income and taxes, respectively. In general, an ownership change as defined by Section 382 results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 % over a three-year period. Since its formation, the Company has raised capital through the issuance of capital stock on several occasions. These financings could result in a change of control as defined by Section 382. The Company has not yet conducted an analysis under Section 382 to determine if historical changes in ownership through December 31, 2024, would limit or otherwise restrict its ability to utilize its NOL and research and development credit carryforwards. In addition, future changes in ownership occurring after December 31, 2024 could affect the limitation in future years, and any limitation may result in expiration of a portion of the NOL or research and development credit carryforwards before utilization. The Company generated research and development tax credits but has not conducted a study to document the qualified activities. This study may result in an adjustment to the Company’s research and development tax credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company’s research and development tax credit carryforwards and, if an adjustment is required, this adjustment would result in an adjustment to the deferred tax asset established for the research and development tax credit carryforwards and the valuation allowance. Beginning in 2022, the Tax Cuts and Jobs Act ("TCJA") amended Section 174 and now requires U.S.-based and non-U.S.-based research and experimental expenditures to be capitalized and amortized over a period of five or 15 years, respectively, for amounts paid in tax years starting after December 31, 2021. Prior to the TCJA amendment, Section 174 allowed taxpayers to immediately deduct research and experimental expenditures in the year paid or incurred. The Company has applied this required change in accounting method beginning in 2022 and the computation may be adjusted pending future IRS guidance. The Company follows the provisions of ASC Topic 740-10, Accounting for Uncertainty in Income Taxes , which specifies how tax benefits for uncertain tax positions are to be recognized, measured, and recorded in financial statements; requires certain disclosures of uncertain tax matters; specifies how reserves for uncertain tax positions should be classified on the consolidated balance sheets; and provides transition and interim period guidance, among other provisions. As of December 31, 2024 and 2023, the Company has not recorded any amounts for uncertain tax positions. The Company’s policy is to recognize interest and penalties accrued on any uncertain tax positions as a component of income tax expense, if any, in its consolidated statements of operations and comprehensive loss. As of December 31, 2024 and 2023, the Company had no reserves for uncertain tax positions. For the years ended December 31, 2024 and 2023, no estimated interest or penalties were recognized on uncertain tax positions. The Company files federal income tax returns in the United States, the Netherlands and Australia and state income tax returns in Massachusetts and various other state jurisdictions. The Company’s tax returns for the years ended December 31, 2019 to December 31, 2024 remain open and subject to examination by the Internal Revenue Service and state taxing authorities.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Net Loss Per Share	14. Net Loss Per Share Basic and diluted net loss per share is computed by dividing net loss by the weighted-average common shares outstanding. The weighted-average common shares outstanding used in the basic and diluted net loss per share calculation includes the pre-funded warrants issued in connection with the Company’s follow-on public offering in June 2023 and registered direct offering in February 2023 as the pre-funded warrants are exercisable for nominal cash consideration. In September 2023, 1,229,224 of the pre-funded warrants were exercised in a cashless transaction which resulted in 1,229,221 shares of common stock being issued to the investor. As of December 31, 2024 , 204,081 pre-funded warrants were outstanding. The following table sets forth the computation of the Company’s basic and diluted net loss per share (in thousands, except share and per share data): ​ Year Ended ​ 2024 2023 Numerator: ​ ​ Net loss ​ $ ( 109,357 ) $ ( 76,429 ) Denominator: ​ ​ Weighted-average common shares outstanding, basic and diluted ​ 27,606,022 ​ 22,315,877 Net loss per share, basic and diluted ​ $ ( 3.96 ) $ ( 3.42 ) The Company has generated a net loss in all periods presented, so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive. The C ompany excluded the following potential common shares from the computation of diluted net loss per share because including them would have had an anti-dilutive effect: ​ December 31, ​ 2024 ​ 2023 Restricted stock units 475,140 — Options to purchase common stock 2,870,364 ​ 2,459,037 Employee stock purchase program ​ 9,003 ​ 4,878

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	15. Commitments and Contingencies Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to its vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims. Legal Proceedings The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the years ended December 31, 2024 and 2023 and, to the best of its knowledge, no material legal proceedings are currently pending or threatened. Payments Upon Termination The Company enters into contracts in the normal course of business with contract research organizations ("CROs"), contract development and manufacturing organizations ("CDMOs") and other third parties for preclinical studies, clinical trials and manufacturing services. These contracts typically do not contain minimum purchase commitments and are generally cancelable by the Company upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including noncancelable obligations of the Company's service providers, up to the date of cancellation and, in the case of certain arrangements with CROs and CDMOs, may include noncancelable fees. Under such agreements, the exact amounts owed by the Company in the event of termination will be based on the timing of the termination and the exact terms of the agreement. As of December 31, 2024 , the Company has not recognized any amounts related to these contingencies as the amount and timing of such payments are not fixed and estimable.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2024
Related Party Transactions [Abstract]
Related Party Transactions	16. Related Party Transactions In June 2024, certain existing investors participated in the Company's underwritten offering (see Note 11 - Stockholders' Equity ). In June 2023, an existing investor participated in the Company’s follow-on offering (see Note 11 - Stockholders' Equity ). In March 2023, the Company executed a promissory note for an aggregate principal amount of $ 0.5 million from an existing investor. The Company did not use these funds and repaid the note four days later, recording a de minimis amount of interest expense based on the then Federal funds rate for short term loans of 4.5 % per annum. In February 2023, certain existing investors participated in the Company’s registered direct offering (see Note 11 - Stockholders' Equity ). The landlord of the Company’s leased office space in Watertown, Massachusetts is a related party of the Company due to its equity ownership.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Segment Information	17. Segment Information The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions, resulting in a single reportable segment. The Company has determined that its Chief Operating Decision Maker ("CODM") is its Chief Executive Officer . The Company’s CODM reviews the Company’s financial information on a consolidated basis for purposes of allocating resources and assessing financial performance. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The Company has not generated any revenue since its inception and does not expect to generate any revenue from the sale of products in the near future. The Company primarily incurs expenses in connection with the research and development of its product candidates as well as selling, general and administrative costs consisting of salaries and related costs for personnel in executive, finance, commercial, corporate and business development, and administrative functions, as well as legal, consulting, commercial planning, market research and professional fees. The key measure of segment profit or loss that the CODM uses to allocate resources and assess performance is the Company’s consolidated net loss, as reported on the consolidated statements of operations and comprehensive loss. In addition, the CODM is regularly provided the following significant segment expense categories which are reviewed against budgeted expectations to assist in resource allocation decision-making : Year Ended 2024 ​ 2023 Bitopertin program external expense $ ( 28,105 ) $ ( 17,271 ) DISC-0974 program external expense ( 16,943 ) ( 9,136 ) DISC-3405 program external expense ( 13,934 ) ( 20,168 ) Other external research and development expense ( 6,879 ) ( 4,752 ) Internal and other research and development expense ( 23,782 ) ( 16,170 ) Selling, general and administrative expense $ ( 23,262 ) $ ( 18,098 ) Stock-based compensation expense $ ( 16,815 ) $ ( 5,530 ) Other segment items* $ 20,363 $ 14,696 Net loss $ ( 109,357 ) $ ( 76,429 ) * Other segment items include interest income, interest expense, other expense, and income tax expense as reported on the consolidated statements of operations and comprehensive loss. Assets regularly provided to the CODM are consistent with those reported on the consolidated balance sheets with particular emphasis on the Company’s available liquidity, including its cash, cash equivalents and marketable securities balances. All of the Company’s tangible assets are held in the United States.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events Milestone Payment In January 2025, the Company dosed the first patient in the Phase 2 clinical trial of DISC-0974. Per the license agreement, a milestone payment of $ 3.0 million was paid to AbbVie on January 31, 2025. For additional details on the license agreement with AbbVie, refer to Note 10 - Development and License Agreements . Underwritten Offering On January 22, 2025, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co. as representatives of the several underwriters listed on Schedule I thereto (the “Underwriters”) related to an underwritten offering of (i) 3,918,182 shares of common stock of the Company, par value $ 0.0001 per share ("Common Stock”) at a price to the public of $ 55.00 per share and (ii) pre-funded warrants to purchase an aggregate of 181,818 shares of Common Stock (the “Pre-Funded Warrants”), at a price to the public of $ 54.9999 per Pre-Funded Warrant, which represents the per share public offering price for the Common Stock less the $ 0.0001 per share exercise price for each such Pre-Funded Warrant. In addition, the Company granted the Underwriters an option exercisable for 30 days from the date of the underwriting agreement to purchase, at the public offering price less any underwriting discounts and commissions, up to an additional 615,000 shares of Common Stock, which the Underwriters exercised in full on January 23, 2025. The net proceeds from the Offering are expected to be approximately $ 243.3 million, which includes the proceeds from the Underwriters' exercise in full of their option to purchase additional shares, after deducting the underwriting discount and estimated offering expenses. The Company will receive nominal proceeds, if any, from the exercise of the Pre-Funded Warrants.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The Company’s consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. Certain reclassifications have been made to prior periods to conform to current period presentation. Reclassification of prior year amounts have been made to separately present accrued external research and development costs from other accrued expenses. There was no impact on total current liabilities or total liabilities resulting from these reclassifications.
Use of Estimates	Use of Estimates The preparation of the Company’s consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to accrued research and development expenses; stock-based compensation expense; the fair value of the common stock prior to the effective date of the merger; and income taxes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it has concluded to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ materially from those estimates or assumptions.
Segment Information	Segment Informatio n The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions, resulting in a single reportable segment. The Company has determined that its chief operating decision maker is its Chief Executive Officer. The Company’s chief operating decision maker reviews the Company’s financial information on a consolidated basis for purposes of allocating resources and assessing financial performance. All of the Company’s tangible assets are held in the United States. See Note 17 - Segment Information for additional details.
Concentration of Credit Risk and of Significant Suppliers	Concentration of Credit Risk and of Significant Suppliers Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and limits its exposure to cash risk by placing its cash with high credit quality accredited financial institutions. The Company has concluded that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and to process its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the manufacturing process or supply chain.
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive income (loss) is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) and the change in accumulated other comprehensive income (loss) for the period. Accumulated other comprehensive income (loss) consisted of foreign currency translation adjustments and unrealized gains (losses) on available-for-sale marketable securities during the year ended December 31, 2024.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking and money market accounts and U.S. treasury securities with original maturities of three months or less at the date of purchase. Cash equivalents are reflected at fair value based on quoted market prices as further described in Note 3 - Fair Value Measurements .
Marketable Securities	Marketable Securities The Company classifies its marketable securities as available-for-sale. All of the Company’s marketable securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date. Marketable securities are maintained by an investment manager and consist of U.S. treasury and government agency securities. Marketable securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income (loss) as a component of stockholders’ equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the underlying marketable security. Although these marketable securities are available to be sold to meet operating needs or otherwise, they are generally held through maturity. The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense), net within the consolidated statements of operations and comprehensive loss. The Company reviews its portfolio of available-for-sale securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit loss or other factors. If the decline in fair value is due to credit loss factors, a loss is recognized. To date, the Company has not experienced any credit losses and does not expect it is exposed to any significant credit risk on these investments.
Deferred Transaction Costs	Deferred Transaction Costs The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred transaction costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the transaction, either as a reduction of the carrying value of the preferred stock or in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the transaction. Should the in-process equity financing be abandoned, the deferred transaction costs would be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss.
Fair Value Measurements	Fair Value Measurements The Company categorizes its assets and liabilities measured at fair value in accordance with the provisions of ASC 820, Fair Value Measurements and Disclosures, which establishes a consistent framework for measuring fair value and expands disclosures for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: • Level 1—Quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level 2—Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and • Level 3—Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing. The fair value of the Company’s cash equivalents are determined according to the fair value hierarchy described above (see Note 3 - Fair Value Measurements ). The carrying values of the Company’s prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Estimated Useful Life Leasehold improvements Shorter of useful life or remaining life of lease Computer equipment 3.0 years Furniture and fixtures 3.0 years Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated in accordance with the above guidelines once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are expensed as incurred. The Company capitalizes internal costs incurred to develop software for internal use during the application development stage. The Company includes capitalized internally developed software subject to a cloud computing arrangement within other assets. Amortization of capitalized internally developed software costs is recorded in depreciation expense over the estimated useful life of the related asset of 3.0 years.
Impairment of Long-lived Assets	Impairment of Long-lived Assets The Company accounts for the impairment and disposition of long-lived assets in accordance with ASC Topic 360, Property, Plant, and Equipment . Long-lived assets, such as property and equipment and right-of-use ("ROU") assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. The recoverability of assets or asset groups to be held and used is measured by a comparison of the carrying amount of an asset or asset group to estimated undiscounted future cash flows expected to be generated by the asset or asset group. If the carrying amount of an asset or asset group exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset or asset group exceeds the estimated fair value of the asset or asset group. There were no impairment losses recorded for the years ended December 31, 2024 and 2023 .
Leases	Leases The Company accounts for its leases under ASC Topic 842, Leases . Upon adoption, the Company elected to combine lease and non-lease components when calculating minimum lease payments on new leases for all asset classes. The Company has also elected an accounting policy to forgo the recognition of lease assets or liabilities for short-term leases. Short-term leases are defined, in accordance with the standard, as those with terms of one year or less and do not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. The Company determines if an arrangement is or contains a lease at contract inception. The Company accounts for a contract as a lease when it has the right to direct the use of the asset for a period of time while obtaining substantially all of the asset’s economic benefits. The Company determines the initial classification and measurement of right-of-use assets and lease liabilities at the lease commencement date and thereafter at the modification date, if modified. Right-of-use assets represent the Company's right to control the underlying assets under lease, and the lease liability is the Company's obligation to make the lease payments related to the underlying assets under lease, over the contractual term. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of future minimum fixed lease payments to be made over the lease term. The Company uses the non-cancellable lease term unless it is reasonably certain that a renewal or termination option will be exercised. When available, the Company will use the rate implicit in the lease to discount lease payments to present value. As most leases do not provide an implicit rate, the Company will estimate the incremental borrowing rate to discount the lease payments. The Company estimates the incremental borrowing rate based on the rates of interest that the Company would have to pay to borrow an amount equal to the lease payments on a collateralized basis, over a similar term, and in a similar economic environment. The right-of-use asset also includes any lease prepayments and initial direct costs, offset by lease incentives. Certain lease agreements contain variable lease payments which are not included in the measurement of the lease liability. Variable lease payments relate to taxes, insurance, utilities, and common area maintenance ("CAM"). These variable lease payments are recognized in the consolidated statements of operations and comprehensive loss in the period in which the obligation for those payments is incurred.
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, depreciation, external costs of vendors engaged to conduct preclinical development activities and clinical trials, manufacturing expenses, as well as the costs of licensing technology. Nonrefundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the services rendered. If the Company acquires an asset or group of assets under an in-licensing arrangement that does not meet the definition of a business under ASC Topic 805, Business Combinations , and the acquired in-process research and development does not have an alternative future use, any related upfront license payment is expensed as incurred in accordance with guidance in ASC Topic 730, Research and Development . Where contingent milestone payments are due to third parties under license or other agreements, the milestone payment obligations are recognized as expense when achievement of the contingent milestone is probable, which is generally upon achievement of the milestone event. Any contingent payments that qualify as a derivative liability are recognized at fair value on the Company’s consolidated balance sheets. Annual maintenance fees under license agreements are expensed in the period in which they are incurred. Contingent payments for assets acquired are expensed as incurred or capitalized and amortized based on the nature of the associated asset at the date the payment is recognized. Royalties owed on sales of the products licensed pursuant to license agreements are expensed in the period the related revenues are recognized. The Company has entered into various research, development and manufacturing contracts with research institutions and other companies primarily in the United States, including contracts with third-party contract research organizations and contract development and manufacturing organizations. These agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. The Company records accrued liabilities for estimated ongoing research, development and manufacturing costs and prepaid expenses for payments made in advance of work performed. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations to those third parties as of period end. Any accrual estimates are based on a number of factors, including the Company’s knowledge of the progress towards completion of the research, development and manufacturing activities, invoicing to date under the contracts, communication from the research institutions and other companies of any actual costs incurred during the period that have not yet been invoiced and the costs included in the contracts. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results may differ from the estimates made by the Company.
Amortization of Debt Discount and Issuance Costs	Amortization of Debt Discount and Issuance Costs Long-term debt is initially recorded as the proceeds received by the Company, net of debt issuance costs and discounts. Debt is subsequently stated at amortized cost. Debt issuance costs and discounts and are amortized to interest expense using the effective interest method, over the term of the debt. Debt issuance costs and discounts related to a recognized debt liability are presented in the consolidated balance sheets as a direct deduction from the carrying amount of that debt liability. For tranches not yet drawn , the related debt issuance costs are deferred and recorded as an asset. In the consolidated statements of cash flows, debt issuance costs paid to lenders are netted against the proceeds from the related long-term debt while debt issuance costs paid to third parties, are presented separately within financing activities.
Patent Costs	Patent Costs The Company expenses all costs as incurred in connection with patent applications, including direct application fees, and the legal and consulting expenses related to making such applications due to the uncertainty about the recovery of the expenditure. These costs are included in selling, general and administrative expenses within the Company’s consolidated statements of operations and comprehensive loss.
Stock-based Compensation	Stock-Based Compensation The Company accounts for all stock-based awards granted to employees and non-employees as stock-based compensation expense at fair value in accordance with ASC 718, Compensation - Stock Compensation . The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the fair value of the Company’s common stock on the date of grant, the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option and the Company’s expected dividend yield. Due to the lack of company-specific historical and implied volatility data, the Company determines the volatility for awards granted based on an analysis of reported data for a group of guideline companies that issued options with substantially similar terms. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of guideline companies. The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company’s stock options granted to employees has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on its common stock; therefore, the expected dividend yield is assumed to be zero. The grant date fair value of restricted stock units and shares of restricted stock granted is based on the fair value of the underlying common stock on the date of grant. The Company recognizes compensation expense for employees and non-employees over the requisite service period, which is generally the vesting period of the respective award, based on the grant date fair value of the award. For awards that include performance-based vesting conditions expense is recognized using the accelerated attribution method when the performance condition is deemed to be probable. The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in the consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. See Note 12 - Stock-Based Compensation for a summary of the stock-based award activity under the Company’s stock-based compensation plans. Determination of Fair Value of Common Stock on Grant Dates Prior to the merger, due to the absence of an active market for Private Disc’s common stock, Private Disc and its Board were required to determine the fair value of Private Disc’s common stock at the time of each grant of a stock-based award. Private Disc estimated the fair value of its common stock utilizing methodologies in accordance with the framework of the American Institute of Certified Public Accountants’ Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation . In determining the exercise prices for options granted, Private Disc considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock has been determined at each grant date based upon a variety of factors, including prices paid for Private Disc’s convertible preferred stock and the rights, preferences, and privileges of Private Disc’s Preferred Stock and common stock; Private Disc’s stage of development and status of technological developments within Private Disc’s research; the illiquid nature of securities in a private company; the prospects of a liquidity event; and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. Private Disc’s common stock valuations were prepared using either an option pricing method (“OPM”), or a hybrid method, both of which used market approaches to estimate our enterprise value. The OPM treats common stock and convertible preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company’s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceeds the value of the convertible preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock. The hybrid method is a probability-weighted expected return method (“PWERM”), by which the equity value in one or more scenarios is calculated using an OPM. The PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values for the company, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. In addition to a scenario using the OPM, the hybrid method also considers an initial public offering scenario in which the shares of convertible preferred stock are assumed to convert to common stock. The future value of the common stock in the initial public offering scenario was discounted back to the valuation date at an appropriate risk adjusted discount rate. In the hybrid method, the present value indicated for each scenario was probability weighted to arrive at an indication of value for the Private Disc’s common stock. Private Disc utilized significant estimates and assumptions in determining the fair value of its equity and equity-based awards. Substantially all of the awards granted by the Company are either new hire grants or routine annual grants. Management evaluates its award grants and modifications contemporaneously and if any are determined to be spring-loaded, the Company will adjust the fair value.
Income Taxes	Income Taxes Income taxes have been accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Since the Company has generated operating losses and expects to continue to incur future losses, the net deferred tax assets have been fully offset by a valuation allowance. The Company accounts for income taxes in accordance with authoritative accounting guidance which states the impact of an uncertain income tax position is recognized at the largest amount that is “more likely than not” to be sustained upon audit by the relevant taxing authority. There are no unrecognized tax benefits included in the Company’s consolidated balance sheets at December 31, 2024 or 2023. The Company’s practice is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties related to income tax matters in its consolidated statements of operations and comprehensive loss since inception. The Company files federal income tax returns in the United States, the Netherlands and Australia and state income tax returns in Massachusetts and various other state jurisdictions. The Company’s income tax returns are subject to review and tax assessment from an income tax examination. As of December 31, 2024 , the Company was not under examination by the Internal Revenue Service or other jurisdictions for any tax year.
Net Loss Per Share	Net Loss Per Share Basic and diluted net loss per share is computed by dividing net loss by the weighted-average common shares outstanding. The weighted-average common shares outstanding used in the basic and diluted net loss per share calculation includes the pre-funded warrants issued in connection with the Company’s follow-on public offering in June 2023 and registered direct offering in February 2023 as the pre-funded warrants are exercisable for nominal cash consideration. In periods in which the Company reports a net loss, diluted net loss per share is generally the same as basic net loss per share since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.
Recently Adopted and Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements On January 1, 2024, the Company adopted ASU 2023-07, Segment Reporting: Improvements to Reportable Segment Disclosures , which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Refer to Note 17 - Segment Information for additional details. Recently Issued Accounting Pronouncements Not Yet Adopted Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Schedule of Property and Equipment Estimated Useful Lives	Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Estimated Useful Life Leasehold improvements Shorter of useful life or remaining life of lease Computer equipment 3.0 years Furniture and fixtures 3.0 years

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	Financial assets and liabilities measured at fair value on a recurring basis are summarized as follows (in thousands): ​ December 31, 2024 ​ Level 1 ​ Level 2 ​ Level 3 Assets ​ ​ ​ Cash equivalents: ​ ​ ​ Money market funds ​ $ 88,735 ​ $ — ​ $ — U.S. treasury securities ​ — ​ 91,916 ​ — Total cash equivalents 88,735 91,916 — Marketable securities: U.S. treasury securities — 189,663 — U.S. government agency securities — 107,784 — Total marketable securities — 297,447 — Total assets ​ $ 88,735 ​ $ 389,363 ​ $ — ​ December 31, 2023 ​ Level 1 Level 2 Level 3 Assets ​ ​ ​ Cash equivalents: ​ ​ ​ Money market funds ​ $ 55,001 ​ $ — ​ $ — U.S. treasury securities ​ — ​ 255,419 ​ — Total cash equivalents 55,001 255,419 — Total assets ​ $ 55,001 ​ $ 255,419 ​ $ —

Marketable Securities (Tables)

Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2024
Marketable Securities [Abstract]
Schedule of Marketable Securities	Marketable securities as of December 31, 2024 consisted of the following (in thousands): ​ Gross Unrealized ​ Amortized Cost ​ Gains ​ Losses ​ Estimated Fair Value Marketable securities available-for-sale: ​ U.S. treasury securities $ 189,409 $ 288 $ ( 34 ) ​ $ 189,663 U.S. government agency securities 107,722 85 ( 23 ) 107,784 Total available-for-sale securities $ 297,131 $ 373 $ ( 57 ) ​ $ 297,447

Cash, Cash Equivalents and Re_2

Cash, Cash Equivalents and Restricted Cash (Tables)	12 Months Ended
	Dec. 31, 2024
Cash and Cash Equivalents [Abstract]
Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash	Cash, cash equivalents and restricted cash consisted of the following (in thousands): ​ December 31, December 31, ​ 2024 ​ 2023 Cash and cash equivalents $ 192,434 $ 360,382 Restricted cash 238 ​ 234 Total cash, cash equivalents and restricted cash as shown on the consolidated statements of cash flows $ 192,672 $ 360,616

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property Plant and Equipment	Property and equipment, net consisted of the following (in thousands): December 31, December 31, 2024 2023 Leasehold improvements $ 566 $ — Furniture and fixtures 355 184 Computer equipment 231 231 Less: Accumulated depreciation ( 401 ) ( 245 ) Property and equipment, net $ 751 $ 170

Other Accrued Expenses (Tables)

Other Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2024
Accrued Liabilities [Abstract]
Summary of Other Accrued Expenses	Other accrued expenses consisted of the following (in thousands): December 31, December 31, 2024 2023 Accrued employee-related expenses $ 7,211 $ 5,790 Accrued professional fees 531 317 Accrued other 355 52 Total other accrued expenses $ 8,097 $ 6,159

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Schedule of Components of Company's Lease Expense and Other Information	The components of lease expense were as follows (in thousands): ​ Year Ended ​ 2024 ​ 2023 Operating lease costs ​ $ 641 ​ $ 422 Variable lease costs ​ 486 ​ 159 Total lease expense ​ $ 1,127 ​ $ 581 Other information related to the Company’s leases is as follows: ​ Year Ended ​ 2024 ​ 2023 Weighted-average remaining lease term ​ 3.5 years ​ 2.9 years Weighted-average discount rate 10.3 % ​ 10.0 %
Schedule of Future Minimum Lease Payments	The following table presents the future minimum lease payments under the Company's lease liabilities as of December 31, 2024, (in thousands): ​ Operating Leases 2025 ​ $ 324 2026 ​ 768 2027 ​ 285 2028 ​ 389 2029 401 Total minimum lease payments ​ $ 2,167 Less: imputed interest ​ ( 489 ) Lease liabilities ​ $ 1,678

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Summary of Obligations Under the Term Loan Facility	The obligations under the Term Loan Facility as of December 31, 2024 consisted of the following (in thousands): December 31, 2024 Principal term loan balance $ 30,000 Unamortized debt discount and issuance costs ( 1,746 ) Accrued end of term fee 68 Long-term debt, net $ 28,322
Scheduled Annual Principal Payments for Term Loan	The annual principal payments due under the Term Loan Facility as of December 31, 2024 were as follows (in thousands): 2025 $ — 2026 — 2027 — 2028 2,200 2029 27,800 Total $ 30,000

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock Option Activity	The following table summarizes stock option activity for the year ended December 31, 2024. Number of ​ Weighted- ​ Weighted- ​ Aggregate Outstanding at December 31, 2023 2,459,037 ​ $ 13.82 ​ 7.81 ​ $ 109,078 Granted 896,275 58.99 ​ ​ Exercised ( 315,266 ) 9.46 ​ ​ Forfeited ( 156,930 ) 40.46 ​ ​ Expired ( 12,752 ) 110.25 ​ ​ Outstanding at December 31, 2024 2,870,364 ​ $ 26.52 7.44 $ 106,766 Exercisable at December 31, 2024 1,589,968 $ 14.72 6.47 $ 77,702
Summary of Fair Value of Stock Option Granted	The weighted-average assumptions used to estimate the fair value of stock options granted were as follows: Year Ended 2024 ​ 2023 Risk-free interest rate 4.00 % ​ 4.03 % Expected term (in years) 6.35 ​ 6.88 Expected volatility 60 % ​ 59 % Expected dividend yield 0 % ​ 0 % Fair value per share of common stock $ 58.99 ​ $ 43.42
Schedule of Restricted Stock Unit Activity	A summary of restricted common stock activity was as follows: December 31, 2023 Unvested at the beginning of the period 1,916 Vested ( 1,916 ) Unvested at the end of the period —
Summary of Stock-based Compensation Expense	Total stock-based compensation expense recorded as research and development and selling, general and administrative expenses, respectively, for employees, directors and non-employees was as follows (in thousands): Year Ended 2024 ​ 2023 Research and development $ 7,028 ​ $ 1,767 Selling, general and administrative 9,787 ​ 3,763 Total stock-based compensation expense $ 16,815 ​ $ 5,530
Summary of Unrecognized Stock-based Compensation	The following table summarizes unrecognized stock-based compensation expense as of December 31, 2024. Unrecognized Expense ​ Weighted-Average Restricted stock units $ 23,284 ​ 3.29 Stock options 28,278 2.85 Total unrecognized equity-based compensation expense $ 51,562
Restricted stock units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Restricted Stock Unit Activity	The following table summarizes restricted stock unit activity for the year ended December 31, 2024. Number of Units ​ Weighted- Restricted stock units as of December 31, 2023 — ​ $ — Granted 507,303 ​ 60.26 Forfeited ( 32,163 ) 63.90 Restricted stock units as of December 31, 2024 475,140 ​ $ 60.01

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Schedule of Reconciliation of the Statutory Federal Income Tax Rate	A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows: ​ Year Ended December 31, ​ 2024 2023 Federal statutory income tax rate ​ 21.0 % 21.0 % State income taxes, net of federal benefit ​ 6.4 % 8.0 % Federal and state research and development tax credits ​ 12.1 % 4.0 % Stock-based compensation 1.3 % 1.3 % Section 162(m) limitation ( 1.6 )% ( 0.8 )% Other ​ ( 0.1 )% 0.1 % Change in deferred tax asset valuation allowance ​ ( 39.4 )% ( 33.6 )% Effective income tax rate ​ ( 0.3 )% 0.0 %
Schedule of Deferred Tax Assets and Liabilities	The significant components of the Company’s net deferred income taxes are as follows (in thousands): ​ December 31, ​ 2024 ​ 2023 Deferred tax assets: ​ ​ Net operating loss carryforwards ​ $ 33,209 $ 24,312 Research and experimental expenditures 39,463 20,598 Tax credits ​ 21,248 ​ 7,202 Capitalized licenses ​ 6,225 ​ 6,890 Accrued expenses 1,137 1,513 Stock-based compensation ​ 3,407 ​ 1,234 Operating lease liabilities ​ 447 ​ 574 Total deferred tax assets ​ 105,136 ​ 62,323 Valuation allowance ​ ( 104,670 ) ​ ( 61,768 ) Total deferred tax assets, net of valuation allowance ​ 466 ​ 555 Deferred tax liabilities: ​ ​ Operating right-of-use assets ​ ( 418 ) ​ ( 527 ) Depreciation ​ ( 48 ) ​ ( 28 ) Total deferred tax liabilities ​ ( 466 ) ​ ( 555 ) Net deferred tax assets ​ $ — $ —

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Summary of Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of the Company’s basic and diluted net loss per share (in thousands, except share and per share data): ​ Year Ended ​ 2024 2023 Numerator: ​ ​ Net loss ​ $ ( 109,357 ) $ ( 76,429 ) Denominator: ​ ​ Weighted-average common shares outstanding, basic and diluted ​ 27,606,022 ​ 22,315,877 Net loss per share, basic and diluted ​ $ ( 3.96 ) $ ( 3.42 )
Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share	The C ompany excluded the following potential common shares from the computation of diluted net loss per share because including them would have had an anti-dilutive effect: ​ December 31, ​ 2024 ​ 2023 Restricted stock units 475,140 — Options to purchase common stock 2,870,364 ​ 2,459,037 Employee stock purchase program ​ 9,003 ​ 4,878

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Schedule of Significant Segment Expense Categories	In addition, the CODM is regularly provided the following significant segment expense categories which are reviewed against budgeted expectations to assist in resource allocation decision-making : Year Ended 2024 ​ 2023 Bitopertin program external expense $ ( 28,105 ) $ ( 17,271 ) DISC-0974 program external expense ( 16,943 ) ( 9,136 ) DISC-3405 program external expense ( 13,934 ) ( 20,168 ) Other external research and development expense ( 6,879 ) ( 4,752 ) Internal and other research and development expense ( 23,782 ) ( 16,170 ) Selling, general and administrative expense $ ( 23,262 ) $ ( 18,098 ) Stock-based compensation expense $ ( 16,815 ) $ ( 5,530 ) Other segment items* $ 20,363 $ 14,696 Net loss $ ( 109,357 ) $ ( 76,429 )

Organization and Nature of th_2

Organization and Nature of the Business - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2024	Jun. 30, 2023
Nature Of Business [Line Items]
Cash and cash equivalents for operations	$ 360,382	$ 192,434
Aggregate costs incurred	$ 1,600
Cash, cash equivalents and short-term marketable securities		$ 489,900
Common stock share exchange value	$ 0.0001	$ 0.0001
Liability incurred under estimated fair value of Company's obligation	$ 0	$ 0	$ 1,500
Change in fair value of contingent value right liability	1,500
Accumulated deficit	$ (188,645)	$ (298,002)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)	12 Months Ended
	Dec. 31, 2024 USD ($) Segment	Dec. 31, 2023 USD ($)
Cash And Cash Equivalents [Line Items]
Impairment losses	$ 0	$ 0
Unrecognized tax benefits	$ 0	$ 0
Number of reporting units | Segment	1
Internally Developed Software [Member]
Cash And Cash Equivalents [Line Items]
Estimated useful lives	3 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Lives (Details)	Dec. 31, 2024
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]	us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember
Computer Equipment [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Life	3 years
Furniture and Fixtures [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Life	3 years

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	$ 297,447
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	88,735	$ 55,001
Marketable securities	0
Total assets	88,735	55,001
Level 1 [Member] | Money Market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	88,735	55,001
Level 1 [Member] | US Treasury Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Marketable securities	0
Level 1 [Member] | US Government Agencies Debt Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	0
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	91,916	255,419
Marketable securities	297,447
Total assets	389,363	255,419
Level 2 [Member] | Money Market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Level 2 [Member] | US Treasury Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	91,916	255,419
Marketable securities	189,663
Level 2 [Member] | US Government Agencies Debt Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	107,784
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Marketable securities	0
Total assets	0	0
Level 3 [Member] | Money Market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Level 3 [Member] | US Treasury Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	0	$ 0
Marketable securities	0
Level 3 [Member] | US Government Agencies Debt Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2023
Liabilities, Fair Value Disclosure [Abstract]
Asset impairment charges	$ 0	$ 0
Fair value of contingent value right liability	$ 0	$ 0	$ 1,500,000

Marketable Securities - Schedul

Marketable Securities - Schedule of Marketable Securities (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	$ 297,131
Gross Unrealized Gains	373
Gross Unrealized Losses	(57)
Estimated Fair Value	297,447
US Treasury Securities [Member]
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	189,409
Gross Unrealized Gains	288
Gross Unrealized Losses	(34)
Estimated Fair Value	189,663
US Government Agencies Debt Securities [Member]
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	107,722
Gross Unrealized Gains	85
Gross Unrealized Losses	(23)
Estimated Fair Value	$ 107,784

Marketable Securities - Additio

Marketable Securities - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) Positions	Dec. 31, 2023 USD ($) Positions
Marketable Securities [Abstract]
Marketable Securities		$ 0
Aggregate fair value of marketable securities in unrealized loss	$ 51,000	$ 0
Number of investments | Positions	5	0
Charges for credit-related impairments	$ 0	$ 0

Cash, Cash Equivalents and Re_3

Cash, Cash Equivalents and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 192,434	$ 360,382
Restricted cash	238	234
Total cash, cash equivalents and restricted cash as shown on the consolidated statements of cash flows	$ 192,672	$ 360,616	$ 194,788

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Property Plant And Equipment [Line Items]
Less: Accumulated depreciation	$ (401)	$ (245)
Property and equipment, net	751	170
Computer Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment	231	231
Furniture and Fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment	355	184
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment	$ 566	$ 0

Property and equipment, net - A

Property and equipment, net - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 0.2	$ 0.1

Other Accrued Expenses - Summar

Other Accrued Expenses - Summary of Other Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Accrued Liabilities [Abstract]
Accrued employee-related expenses	$ 7,211	$ 5,790
Accrued professional fees	531	317
Accrued other	355	52
Total other accrued expenses	$ 8,097	$ 6,159

Leases - Additional Information

Leases - Additional Information (Details) $ in Millions	1 Months Ended	12 Months Ended
	Aug. 31, 2024 USD ($) ft²	Dec. 31, 2024 USD ($)
Lessee, Lease, Description [Line Items]
Sublease expiration date		Nov. 30, 2026
Lease expiration date		Dec. 31, 2029
Area of office space | ft²	7,566
Additional right-of-use asset	$ 0.1
Additional lease liability	0.1
Tenant improvement allowance	0.5
Tenant improvement allowance reimbursements		$ 0.5
Forward Starting Lease [Member]
Lessee, Lease, Description [Line Items]
Tenant improvement allowance	0.3
Undiscounted lease payments due, net	$ 1

Leases - Schedule of Components

Leases - Schedule of Components of Company's Lease Expense and Other Information (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Operating lease costs	$ 641	$ 422
Variable lease costs	486	159
Total lease expense	$ 1,127	$ 581

Leases - Schedule of Componen_2

Leases - Schedule of Components of Company's Lease Expense and Other Information (Details 2)	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Weighted average remaining lease term	3 years 6 months	2 years 10 months 24 days
Weighted average discount rate	10.30%	10%

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2025	$ 324
2026	768
2027	285
2028	389
2029	401
Total minimum lease payments	2,167
Less imputed interest	(489)
Lease liabilities	$ 1,678

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Details) - USD ($) $ in Thousands		12 Months Ended
	Nov. 06, 2024	Dec. 31, 2024
Term Loan [Member]
Line Of Credit Facility [Line Items]
Debt discount and debt issuance costs		$ 1,746
Final end of term charge accrued	$ 2,000
Term Loan [Member] | Hercules Loan Agreement [Member]
Line Of Credit Facility [Line Items]
Term loan facility	200,000
Borrowed an initial term loan facility	$ 30,000
Maturity Date	Dec. 01, 2029
Interest Rate	8.25%
Prepayment charge, percentage	3%
Prepayment Charge, Percentage After Eighteen Months	2%
Prepayment Charge, Percentage Thereafter	1%
Debt discount and debt issuance costs	$ 1,800
Term loan exit fee rate	6.75%
Unamortized deferred financing costs		600
Final end of term charge accrued		100
Interest expense		$ 600
Term Loan [Member] | Hercules Loan Agreement [Member] | Prime Rate [Member]
Line Of Credit Facility [Line Items]
Interest Rate	1.75%
Term Loan [Member] | Hercules Loan Agreement [Member] | Minimum [Member]
Line Of Credit Facility [Line Items]
Aggregate minimum principal amount	$ 50,000
Market capitalization covenant	1,000,000
Tranche One [Member] | Hercules Loan Agreement [Member]
Line Of Credit Facility [Line Items]
Additional term loan	80,000
Tranche Two and Three [Member] | Term Loan [Member] | Hercules Loan Agreement [Member]
Line Of Credit Facility [Line Items]
Additional term loan	65,000
Tranche Four [Member] | Term Loan [Member] | Hercules Loan Agreement [Member]
Line Of Credit Facility [Line Items]
Additional term loan	$ 25,000

Long-Term Debt - Summary of Obl

Long-Term Debt - Summary of Obligations Under the Term Loan Facility (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Long-term debt, net	$ 28,322	$ 0
Term Loan [Member]
Debt Instrument [Line Items]
Principal term loan balance	30,000
Unamortized debt discount and issuance costs	(1,746)
Accrued end of term fee	68
Long-term debt, net	$ 28,322

Long-Term Debt - Scheduled Annu

Long-Term Debt - Scheduled Annual Principal Payments for Term Loan (Details) - Term Loan [Member] $ in Thousands	Dec. 31, 2024 USD ($)
Debt Instrument [Line Items]
2025	$ 0
2026	0
2027	0
2028	2,200
2029	27,800
Total	$ 30,000

Development and License Agree_2

Development and License Agreements - Additional Information (Details) - USD ($)	1 Months Ended					3 Months Ended	12 Months Ended
	Oct. 31, 2023	Jan. 31, 2023	May 31, 2021	Mar. 31, 2021	Sep. 30, 2019	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 29, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense							$ 96,671,000	$ 69,264,000
License and Stock Purchase Agreement [Member] | AbbVie [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment							0
Non refundable upfront fee					$ 600,000
License Agreement [Member] | OBB [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received							200,000
Future milestone recievable							0
License Agreement [Member] | OBB [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future consideration recievable on clinical							7,000,000
Future consideration recievable on regulatory							35,000,000
Future consideration recievable on sales milestones							160,000,000
License Agreement [Member] | Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment							0
Non-refundable upfront payment			$ 4,000,000	$ 500,000
Number of shares issued									482,313
License Agreement [Member] | Mabwell [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense							$ 100,000	$ 15,000,000
Upfront payment						$ 10,000,000
Development and Regulatory Milestone First Indication [Member] | License Agreement [Member] | Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment			50,000,000
Development and Regulatory First Indication First Milestone [Member] | License Agreement [Member] | Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment			10,000,000
Development and Regulatory First Indication First Milestone [Member] | License Agreement [Member] | Mabwell [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments	$ 5,000,000
Development and Regulatory Milestone Second Indication [Member] | License Agreement [Member] | Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment			35,000,000
Development and Regulatory First Indication Second Milestone [Member] | License Agreement [Member] | Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment			15,000,000
Development and Regulatory First Indication Second Milestone [Member] | License Agreement [Member] | Mabwell [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment		$ 10,000,000
Development and Regulatory Second Indication First Milestone [Member] | License Agreement [Member] | Mabwell [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment		5,000,000
Development and Regulatory [Member] | License Agreement [Member] | Mabwell [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment		127,500,000
Development [Member] | License and Stock Purchase Agreement [Member] | AbbVie [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment					18,000,000
Commercialization [Member] | License and Stock Purchase Agreement [Member] | AbbVie [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment					45,000,000
Sales-based [Member] | License and Stock Purchase Agreement [Member] | AbbVie [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment					$ 87,500,000
Sales-based [Member] | License Agreement [Member] | Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment			$ 120,000,000
Sales-based [Member] | License Agreement [Member] | Mabwell [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment		$ 275,000,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions

1 Months Ended

6 Months Ended

12 Months Ended

Nov. 15, 2024

Dec. 05, 2023

Jun. 30, 2024

Nov. 30, 2023

Oct. 31, 2023

Jun. 30, 2023

Feb. 28, 2023

Jan. 31, 2023

Jun. 30, 2024

Dec. 31, 2024

Dec. 31, 2023

Sep. 30, 2023

Class of Stock [Line Items]

Preferred stock, shares authorized

10,000,000

10,000,000

Preferred stock, par value (in Dollars per share)

$ 0.0001

$ 0.0001

Preferred stock, shares issued

0

0

Preferred stock, shares outstanding

0

0

Common stock, shares authorized

100,000,000

100,000,000

Common stock, par value (in Dollars per share)

$ 0.0001

$ 0.0001

Common stock, shares issued

29,865,030

24,360,233

Common stock, shares outstanding

29,865,030

24,360,233

Registered Direct Offering [Member]

Class of Stock [Line Items]

Common stock, shares issued

1,229,221

Sale of common stock, shares

1,488,166

Offering expenses

$ 0.1

Sale of common stock, price per share

$ 23

Purchase of common stock for pre-funded warrants, shares

1,229,224

Sale of pre-funded warrant, price per warrant

$ 22.9999

Sale of pre funded warrant and common stock net proceeds

$ 62.4

Follow-On Public Offering [Member]

Class of Stock [Line Items]

Common stock reserved for the exercise of pre-funded warrants

204,081

Common stock, shares issued

3,015,919

Shares issued, price per share

$ 49

Offering expenses

$ 9.9

Purchase of common stock for pre-funded warrants, shares

204,081

Sale of pre-funded warrant, price per warrant

$ 48.9999

Sale of pre funded warrant net proceeds

$ 147.9

Pre-funded warrant, beneficiary ownership limitation percentage

19.99%

Description of initial ownership limit

Purchasers of the pre-funded warrants may also elect to set the initial Ownership Limit at 4.99%, 9.99% or 19.99%.

Cantor ATM Agreement [Member]

Class of Stock [Line Items]

Common stock, par value (in Dollars per share)

$ 0.0001

Aggregate future offer, issuance and sale

$ 200

$ 0

Jefferies LLC ATM Agreement [Member]

Class of Stock [Line Items]

Sale of common stock, shares

234,449

141,914

Aggregate future offer, issuance and sale

$ 400

$ 59.7

Offering expenses

$ 0.6

Proceeds from sale of common stock

15.3

$ 7.2

Net proceeds, after deducting placement agent fees and offering expenses

$ 14.8

$ 7

Jefferies LLC November 2023 ATM Agreement [Member]

Class of Stock [Line Items]

Sale of common stock, shares

376,363

Proceeds from sale of common stock

$ 22.5

Net proceeds, after deducting placement agent fees and offering expenses

$ 21.8

SVB Securities LLC ATM Agreement [Member]

Class of Stock [Line Items]

Sale of common stock, shares

825,350

Aggregate future offer, issuance and sale

$ 300

Offering expenses

$ 0.3

Proceeds from sale of common stock

20

Net proceeds, after deducting placement agent fees and offering expenses

$ 19.5

June Two Thousand and Twenty Four Underwritten Offering [Member]

Class of Stock [Line Items]

Common stock, par value (in Dollars per share)

$ 0.0001

$ 0.0001

Common stock, shares issued

4,944,000

4,944,000

Shares issued, price per share

$ 36

$ 36

Offering expenses

$ 5.5

Proceeds from sale of common stock

$ 172.5

Gemini Merger [Member]

Class of Stock [Line Items]

Common stock, shares issued

1,672,599

Sale of common stock, shares

12,635,956

2021 Plan [Member] | Gemini Merger [Member]

Class of Stock [Line Items]

Common stock reserved and available for future issuance

2,035,103

2021 Employee Stock Purchase Plan [Member] | Gemini Merger [Member]

Class of Stock [Line Items]

Common stock reserved and available for future issuance

180,894

Minimum [Member] | Registered Direct Offering [Member]

Class of Stock [Line Items]

Pre-funded warrant, beneficiary ownership limitation percentage

9.99%

Pre-funded warrant, beneficiary ownership limitation percentage under the notice period

19.99%

Minimum [Member] | Follow-On Public Offering [Member]

Class of Stock [Line Items]

Pre-funded warrant, beneficiary ownership limitation percentage

24.99%

Minimum [Member] | Jefferies LLC ATM Agreement [Member]

Class of Stock [Line Items]

Aggregate future offer, issuance and sale

$ 59.7

Maximum [Member] | Follow-On Public Offering [Member]

Class of Stock [Line Items]

Option Shares Available To Purchase For Underwriter

420,000

Pre-funded warrant, beneficiary ownership limitation percentage

24.99%

Maximum [Member] | Jefferies LLC ATM Agreement [Member]

Class of Stock [Line Items]

Aggregate future offer, issuance and sale

$ 200

Maximum [Member] | SVB Securities LLC ATM Agreement [Member]

Class of Stock [Line Items]

Aggregate future offer, issuance and sale

$ 100

Investors Or Affiliates [Member] | Registered Direct Offering [Member]

Class of Stock [Line Items]

Ownership of investors in company's capital stock

5%

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Feb. 03, 2021	Dec. 31, 2024	Dec. 31, 2023	Jan. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation outstanding shares		2,870,364	2,459,037
Share-based Payment Arrangement, Expense		$ 16,815	$ 5,530
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 14,500	$ 8,300
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 35.36	$ 26.54
Common Stock, Par or Stated Value Per Share		$ 0.0001	$ 0.0001
Expected dividend yield		0%	0%
Granted		896,275
Fair value of stock options vested		$ 10,000	$ 3,700
Common stock shares issued		29,865,030	24,360,233
Tax benefit from the exercise of options eligible for a tax deduction		$ 11,000	$ 7,200
Share-Based Payment Arrangement, Expense		$ 16,815	$ 5,530
Exercisable at December 31, 2024		$ 14.72
Restricted stock units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted		$ 60.26
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		3 years 3 months 14 days
Restricted Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares issued		63,061
Restricted Common Stock [Member] | Founders And Certain Employees [Member] | Disc Medicine Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common Stock, Par or Stated Value Per Share		$ 0.0001
2021 Inducement Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for options grant		161,689
2021 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for options grant		254,926
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum		1%
Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)		43,055
Out-Of-Plan Inducement Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period		36 months
Common stock shares issued			0
Out-Of-Plan Inducement Grants [Member] | Restricted stock units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage		25%
Granted		146,664
Out-Of-Plan Inducement Grants [Member] | Nonqualified Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage		25%
Granted		220,000
2021 Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum percent of fair market value of common stock	100%
Vesting period		4 years
Number of shares available for options grant		1,643,165
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum		4%
Gemini Merger [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares issued				1,672,599
Gemini Merger [Member] | 2021 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares of common stock reserved				180,894
Common Stock, Capital Shares Reserved for Future Issuance				180,894
Gemini Merger [Member] | 2021 Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares of common stock reserved				2,035,103
Common Stock, Capital Shares Reserved for Future Issuance				2,035,103

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Fair Value of Stock Option Granted (Details) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate	4%	4.03%
Expected term (in years)	6 years 4 months 6 days	6 years 10 months 17 days
Expected volatility	60%	59%
Expected dividend yield	0%	0%
Fair value per share of common stock	$ 58.99	$ 43.42

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Outstanding at December 31, 2023	2,459,037
Granted	896,275
Exercised	(315,266)
Forfeited	(156,930)
Expired	(12,752)
Outstanding at December 31, 2024	2,870,364	2,459,037
Exercisable at December 31, 2024	1,589,968
Outstanding at December 31, 2023	$ 13.82
Granted	58.99
Exercised	9.46
Forfeited	40.46
Expired	110.25
Outstanding at December 31, 2024	26.52	$ 13.82
Exercisable at December 31, 2024	$ 14.72
Weighted-Average Remaining Contractual Term, Outstanding	7 years 5 months 8 days	7 years 9 months 21 days
Exercisable at December 31, 2024	6 years 5 months 19 days
Aggregate intrinsic value, Outstanding	$ 106,766	$ 109,078
Exercisable at December 31, 2024	$ 77,702

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Restricted Stock Unit Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Restricted stock units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested at the beginning of the period	0
Granted	507,303
Forfeited	(32,163)
Unvested at the end of the period	475,140	0
Beginning period, December 31, 2023	$ 0
Granted	60.26
Forfeited	63.9
Ending period, December 31, 2024	$ 60.01	$ 0
Restricted Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested at the beginning of the period	0	1,916
Vested		(1,916)
Unvested at the end of the period		0

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 16,815	$ 5,530
Research and Development
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	7,028	1,767
Selling, General and Administrative
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 9,787	$ 3,763

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Unrecognized Stock-based Compensation (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 51,562
Restricted stock units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 23,284
Weighted-Average Remaining Period of Recognition	3 years 3 months 14 days
Employee Stock Option
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 28,278
Weighted-Average Remaining Period of Recognition	2 years 10 months 6 days

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating Loss Carryforwards [Line Items]
Valuation allowance, deferred tax asset, increase	$ 42,900
State income tax expense	$ 355	$ 99
Minimum [Member]
Operating Loss Carryforwards [Line Items]
Percentage of change in ownership	50%
Research
Operating Loss Carryforwards [Line Items]
R&D tax credit carryforwards expiration year	2034
Federal
Operating Loss Carryforwards [Line Items]
Research and development tax credits carryforwards	$ 19,000
Operating loss carryforwards	$ 117,900
R&D tax credit carryforwards expiration year	2037
State
Operating Loss Carryforwards [Line Items]
State income tax expense	$ 400	$ 100
Research and development tax credits carryforwards	2,800
Operating loss carryforwards	$ 133,800

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of the Statutory Federal Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Federal statutory income tax rate	21%	21%
State income taxes, net of federal benefit	6.40%	8%
Federal and state research and development tax credits	12.10%	4%
Stock-based compensation	1.30%	1.30%
Section 162(m) limitation	(1.60%)	(0.80%)
Other	(0.10%)	0.10%
Change in deferred tax asset valuation allowance	(39.40%)	(33.60%)
Effective income tax rate	(0.30%)	0%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Deferred tax assets:
Net operating loss carryforwards	$ 33,209	$ 24,312
Research and experimental expenditures	39,463	20,598
Tax credits	21,248	7,202
Capitalized licenses	6,225	6,890
Accrued expenses	1,137	1,513
Stock-based compensation	3,407	1,234
Operating lease liabilities	447	574
Total deferred tax assets	105,136	62,323
Valuation allowance	(104,670)	(61,768)
Total deferred tax assets, net of valuation allowance	466	555
Deferred tax liabilities:
Operating right-of-use assets	(418)	(527)
Depreciation	(48)	(28)
Total deferred tax liabilities	(466)	(555)
Net deferred tax assets	$ 0	$ 0

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Earnings Per Share [Abstract]
Net loss	$ (109,357)	$ (76,429)
Weighted-average common shares outstanding-basic	27,606,022	22,315,877
Weighted-average common shares outstanding-diluted	27,606,022	22,315,877
Net loss per share, basic	$ (3.96)	$ (3.42)
Net loss per share, diluted	$ (3.96)	$ (3.42)

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Restricted stock units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	475,140	0
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	2,870,364	2,459,037
Employee Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	9,003	4,878

Net Loss Per Share - Additional

Net Loss Per Share - Additional Information (Details) - shares	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2024
Earnings Per Share [Abstract]
Exercise of pre-funded warrants shares	1,229,224
Issuance of common stock upon exercise of warrants	1,229,221
Pre-funded warrants outstanding		204,081

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) $ in Millions	Mar. 31, 2023 USD ($)
Related Party Transaction [Line Items]
Debt Instrument, Face Amount	$ 0.5
Short Term Bank Loans And NotesPayable Percentage	4.50%

Segment Information - Additiona

Segment Information - Additional Information (Details)	12 Months Ended
	Dec. 31, 2024 Segment
Segment Reporting [Abstract]
Number of reporting units	1
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]	srt:ChiefExecutiveOfficerMember
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description	The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The Company has not generated any revenue since its inception and does not expect to generate any revenue from the sale of products in the near future. The Company primarily incurs expenses in connection with the research and development of its product candidates as well as selling, general and administrative costs consisting of salaries and related costs for personnel in executive, finance, commercial, corporate and business development, and administrative functions, as well as legal, consulting, commercial planning, market research and professional fees.The key measure of segment profit or loss that the CODM uses to allocate resources and assess performance is the Company’s consolidated net loss, as reported on the consolidated statements of operations and comprehensive loss. In addition, the CODM is regularly provided the following significant segment expense categories which are reviewed against budgeted expectations to assist in resource allocation decision-making

Segment Information - Schedule

Segment Information - Schedule of Significant Segment Expense Categories (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
Research and development personnel-related expense	$ (96,671)	$ (69,264)
Selling, general and administrative expense	(33,049)	(21,861)
Stock-based compensation expense	(16,815)	(5,530)
Net loss	(109,357)	(76,429)
Significant Segment Expense Category [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative expense	(23,262)	(18,098)
Stock-based compensation expense	(16,815)	(5,530)
Other Segment Items [Member]
Segment Reporting Information [Line Items]
Other segment items	20,363	14,696
Key Measure of Segment Profit or Loss [Member]
Segment Reporting Information [Line Items]
Net loss	(109,357)	(76,429)
Bitopertin [Member] | Significant Segment Expense Category [Member]
Segment Reporting Information [Line Items]
Research and development personnel-related expense	(28,105)	(17,271)
DISC-0974 [Member] | Significant Segment Expense Category [Member]
Segment Reporting Information [Line Items]
Research and development personnel-related expense	(16,943)	(9,136)
DISC-3405 [Member] | Significant Segment Expense Category [Member]
Segment Reporting Information [Line Items]
Research and development personnel-related expense	(13,934)	(20,168)
Other Research [Member] | Significant Segment Expense Category [Member]
Segment Reporting Information [Line Items]
Research and development personnel-related expense	(6,879)	(4,752)
Internal Research and Development [Member] | Significant Segment Expense Category [Member]
Segment Reporting Information [Line Items]
Research and development personnel-related expense	$ (23,782)	$ (16,170)

Segment Information - Schedul_2

Segment Information - Schedule of Significant Segment Expense Categories (Parentheticals) (Details)	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Segment Reporting, Other Segment Item, Composition, Description	Other segment items include interest income, interest expense, other expense, and income tax expense as reported on the consolidated statements of operations and comprehensive loss.

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended
	Jan. 22, 2025	Jan. 31, 2025	Jan. 23, 2025	Dec. 31, 2024	Dec. 31, 2023
Subsequent Event [Line Items]
Common stock, shares issued				29,865,030	24,360,233
Common stock, par value (in Dollars per share)				$ 0.0001	$ 0.0001
License Agreement [Member] | AbbVie [Member] | Subsequent Event [Member] | Development First Milestone [Member]
Subsequent Event [Line Items]
Milestone payments		$ 3
January 2025 Underwritten Offering [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock, shares issued	3,918,182		615,000
Common stock, par value (in Dollars per share)	$ 0.0001
Shares issued, price per share	$ 55
Purchase of common stock for pre-funded warrants, shares	181,818
Sale of pre-funded warrant, price per warrant	$ 54.9999
Pre-funded warrant, exercise price per warrant	$ 0.0001
Net proceeds from offering	$ 243.3